Header Logo

SHANNON NEVILLE WESTIN

TitleAssociate Professor
InstitutionMD Anderson
DepartmentGynecological Oncology & Reproductive Medicine
Address1155 Pressler St
Houston TX 77030-3721
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Awasthi S, Dobrolecki LE, Sallas C, Zhang X, Li Y, Khazaei S, Ghosh S, Jeter CR, Liu J, Mills GB, Westin SN, Lewis MT, Peng W, Sood AK, Yap TA, Yi SS, McGrail DJ, Sahni N. UBA1 inhibition sensitizes cancer cells to PARP inhibitors. Cell Rep Med. 2024 Dec 17; 5(12):101834. PMID: 39626673.
      Citations:    Fields:    Translation:HumansAnimalsCells
    2. Bowen MB, Melendez B, Zhang Q, Yang RK, Fellman BM, Lawson BC, Adjei NN, Celestino J, Wani KM, Singh B, Urbauer DL, Lazar AJ, Lu KH, Wargo JA, Westin SN, Yates MS, Bowen MB, Melendez B, Zhang Q, Yang RK, Fellman BM, Lawson BC, Adjei NN, Celestino J, Wani KM, Singh B, Urbauer DL, Lazar AJ, Lu KH, Wargo JA, Westin SN, Yates MS. Long-Term Follow-up of Levonorgestrel Intrauterine Device for Atypical Hyperplasia and Early Endometrial Cancer Reveals Relapse Characterized by Immune Exhaustion. Clin Cancer Res. 2024 Nov 15; 30(22):5073-5082. PMID: 38922360; PMCID: PMC11567806.
      Citations: 1     Fields:    Translation:HumansCellsCTClinical Trials
    3. Nitecki Wilke R, Liu J, Westin SN, Fellman BM, Sims TT, Pham M, Rangel K, Sey E, Rauh-Hain JA, Lu KH, Sood AK, Fleming ND. The association of the chemotherapy response score and homologous recombination deficiency in patients undergoing interval tumor reductive surgery following neoadjuvant chemotherapy. Int J Gynecol Cancer. 2024 Oct 16. PMID: 39414313.
      Citations:    Fields:    
    4. Adjei NN, Bowen MB, Wilke RN, Yates MS, Westin SN. Uterine-Conserving Treatment Options for Atypical Endometrial Hyperplasia and Early Endometrial Cancer. Curr Oncol Rep. 2024 Nov; 26(11):1367-1379. PMID: 39361076.
      Citations:    Fields:    Translation:Humans
    5. Brown J, Miller A, Holman LL, Backes F, Nagel C, Bender D, Miller DS, Powell MA, Westin SN, Bonebrake A, Muller CY, Secord AA, Crane E, Schorge J, Tew WP, Sood AK, Bookman MA, Aghajanian C, Gershenson DM. Results of a randomized phase II trial of paclitaxel and carboplatin versus bleomycin, etoposide and cisplatin for newly diagnosed and recurrent Chemonaive stromal ovarian tumors: An NRG oncology/gynecologic oncology group study14. Gynecol Oncol. 2024 Nov; 190:283-290. PMID: 39265466.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    6. How JA, Jazaeri AA, Westin SN, Lawson BC, Klopp AH, Soliman PT, Lu KH. Translating biological insights into improved management of endometrial cancer. Nat Rev Clin Oncol. 2024 Nov; 21(11):781-800. PMID: 39198622.
      Citations: 1     Fields:    Translation:Humans
    7. How JA, Dang M, Lee S, Fellman B, Westin SN, Sood AK, Fleming ND, Shafer A, Yuan Y, Liu J, Zhao L, Celestino J, Hajek R, Morgan MB, Parra ER, Laberiano Fernandez CD, Arrechedera CA, Solis Soto LM, Schmeler KM, Nick A, Lu KH, Coleman R, Wang L, Jazaeri AA. Pembrolizumab plus chemotherapy in frontline treatment of advanced ovarian cancer: Clinical and translational results from a phase 2 trial. Med. 2024 Aug 10. PMID: 39151421.
      Citations:    Fields:    
    8. Son J, Zhang Y, Lin H, Mirallas O, Alvarez Ballesteros P, Nardo M, Clark N, Hillman RT, Campbell E, Holla V, Johnson AM, Biter AB, Yuan Y, Cobb LP, Gershenson DM, Jazaeri AA, Lu KH, Soliman PT, Westin SN, Euscher ED, Lawson BC, Yang RK, Meric-Bernstam F, Hong DS, Son J, Zhang Y, Lin H, Mirallas O, Alvarez Ballesteros P, Nardo M, Clark N, Hillman RT, Campbell E, Holla V, Johnson AM, Biter AB, Yuan Y, Cobb LP, Gershenson DM, Jazaeri AA, Lu KH, Soliman PT, Westin SN, Euscher ED, Lawson BC, Yang RK, Meric-Bernstam F, Hong DS. Clinical and Genomic Landscape of RAS Mutations in Gynecologic Cancers. Clin Cancer Res. 2024 Jul 15; 30(14):2986-2995. PMID: 38687597; PMCID: PMC11250057.
      Citations: 3     Fields:    Translation:Humans
    9. Hutchcraft ML, Rios-Doria E, Sia TY, Teplinsky E, Westin SN, Nelson G. #HashtagThis - Everything you need to know about launching your gynecologic oncology social media research career: A report from Gynecologic Oncology Reports and Society of Gynecologic Oncology Education Committee. Gynecol Oncol Rep. 2024 Aug; 54:101451. PMID: 39045261; PMCID: PMC11263937.
      Citations:    
    10. Kim ST, Chu Y, Misoi M, Suarez-Almazor ME, Tayar JH, Lu H, Buni M, Kramer J, Rodriguez E, Hussain Z, Neelapu SS, Wang J, Shah AY, Tannir NM, Campbell MT, Gibbons DL, Cascone T, Lu C, Blumenschein GR, Altan M, Lim B, Valero V, Loghin ME, Tu J, Westin SN, Naing A, Garcia-Manero G, Abdel-Wahab N, Tawbi HA, Hwu P, Oliva ICG, Davies MA, Patel SP, Zou J, Futreal A, Diab A, Wang L, Nurieva R. Author Correction: Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy. Nat Commun. 2024 Jul 04; 15(1):5621. PMID: 38965214; PMCID: PMC11224259.
      Citations:    Fields:    
    11. Lawson BC, Marques-Piubelli ML, Westin SN, Malpica A. Folate Receptor Immunohistochemical Staining and Gynecologic Tumors: Initial Experience With 216 Cases. Int J Gynecol Pathol. 2024 Jun 12. PMID: 38914019.
      Citations:    Fields:    
    12. Knisely A, Hinchcliff EM, Gardiner E, Rangwala R, Lito K, Fellman B, Yuan Y, Sood AK, Westin SN, Lu KH, Jazaeri AA. Phase 1b study of batiraxcept in combination with durvalumab in patients with platinum-resistant ovarian cancer. iScience. 2024 May 17; 27(5):109801. PMID: 38726365; PMCID: PMC11079458.
      Citations:    
    13. Wagner P, Levine EA, Kim AC, Shen P, Fleming ND, Westin SN, Berry LK, Karakousis GC, Tanyi JL, Olson MT, Madajewski B, Ostrander B, Krishnan K, Balch CM, Bartlett DL. Detection of Residual Peritoneal Metastases Following Cytoreductive Surgery Using Pegsitacianine, a pH-Sensitive Imaging Agent: Final Results from a Phase II Study. Ann Surg Oncol. 2024 Jul; 31(7):4726-4734. PMID: 38622456.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    14. Flores Legarreta A, Saab R, Gonzales NR, Chisholm GB, Westin SN, Hillman RT, Frumovitz M. Neuroendocrine neoplasms of the ovary: a review of 63 cases. Int J Gynecol Cancer. 2024 Apr 01; 34(4):566-573. PMID: 38290783.
      Citations:    Fields:    Translation:Humans
    15. Knisely A, Hinchcliff E, Fellman B, Mosley A, Lito K, Hull S, Westin SN, Sood AK, Schmeler KM, Taylor JS, Huang SY, Sheth RA, Lu KH, Jazaeri AA. Phase 1b study of intraperitoneal ipilimumab and nivolumab in patients with recurrent gynecologic malignancies with peritoneal carcinomatosis. Med. 2024 Apr 12; 5(4):311-320.e3. PMID: 38471508; PMCID: PMC11015975.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    16. Bogani G, Monk BJ, Powell MA, Westin SN, Slomovitz B, Moore KN, Eskander RN, Raspagliesi F, Barretina-Ginesta MP, Colombo N, Mirza MR. Adding immunotherapy to first-line treatment of advanced and metastatic endometrial cancer. Ann Oncol. 2024 May; 35(5):414-428. PMID: 38431043.
      Citations: 10     Fields:    Translation:Humans
    17. Joseph R, Dasari SK, Umamaheswaran S, Mangala LS, Bayraktar E, Rodriguez-Aguayo C, Wu Y, Nguyen N, Powell RT, Sobieski M, Liu Y, Kim MS, Corvigno S, Foster K, Hanjra P, Vu TC, Chowdhury MA, Amero P, Stephan C, Lopez-Berestein G, Westin SN, Sood AK. EphA2- and HDAC-Targeted Combination Therapy in Endometrial Cancer. Int J Mol Sci. 2024 Jan 20; 25(2). PMID: 38279277; PMCID: PMC10816153.
      Citations: 2     Fields:    Translation:HumansAnimalsCells
    18. How JA, Legarreta AF, Handley KF, Fellman B, Foster KI, Glassman D, Vuttaradhi VK, Brodsky AL, Lawson B, Frumovitz M, Westin SN, Ramondetta LM, Gershenson DM, Sood AK, Hillman RT. Serial cytoreductive surgery and survival outcomes in recurrent adult-type ovarian granulosa cell tumors. Am J Obstet Gynecol. 2024 05; 230(5):544.e1-544.e13. PMID: 38191019; PMCID: PMC11152250.
      Citations:    Fields:    Translation:Humans
    19. Li Y, Dobrolecki LE, Sallas C, Zhang X, Kerr TD, Bisht D, Wang Y, Awasthi S, Kaundal B, Wu S, Peng W, Mendillo ML, Lu Y, Jeter CR, Peng G, Liu J, Westin SN, Sood AK, Lewis MT, Das J, Yi SS, Bedford MT, McGrail DJ, Sahni N. PRMT blockade induces defective DNA replication stress response and synergizes with PARP inhibition. Cell Rep Med. 2023 12 19; 4(12):101326. PMID: 38118413; PMCID: PMC10772459.
      Citations: 2     Fields:    Translation:HumansCells
    20. Hinchcliff EM, Knisely A, Adjei N, Fellman B, Yuan Y, Patel A, Xu C, Westin SN, Sood AK, Soliman PT, Shafer A, Fleming ND, Gershenson DM, Vikram R, Bathala T, Vining D, Ganeshan DM, Lu KH, Sun CC, Meyer LA, Jazaeri AA. Randomized phase 2 trial of tremelimumab and durvalumab in combination versus sequentially in recurrent platinum-resistant ovarian cancer. Cancer. 2024 04 01; 130(7):1061-1071. PMID: 38009662; PMCID: PMC11267492.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    21. Jazaeri AA, Grisham R, Knisely A, Spranger S, Zamarin D, Hillman RT, Lawson BC, Burns KH, Lee S, Westin SN, Moiso E, Williams MJ, Bardhan NM, Pisanic T, Matulonis U, Weigelt B, Shih I, Konstantinopoulos PA, Gaillard S, Wang L, Aghajanian C, D'Andrea AD, Hammond P, Shah S, Wucherpfennig KW, Lu KH. Transforming ovarian cancer care by targeting minimal residual disease. Med. 2023 11 10; 4(11):755-760. PMID: 37951209; PMCID: PMC11275633.
      Citations:    Translation:Humans
    22. Hong H, Glassman D, Westin SN. Ischemic bowel associated with newly diagnosed patent foramen ovale. Int J Gynecol Cancer. 2023 11 06; 33(11):1833-1834. PMID: 37666526.
      Citations:    Fields:    Translation:Humans
    23. Westin SN, Moore K, Chon HS, Lee JY, Sundborg M, Shai A, Nishio S, Gold MA, McIntyre K, Tillmanns TD, Blank SV, Liu JH, McCollum M, Nishikawa T, Pennington K, Novak Z, De Melo AC, Papadimitriou C, Gil-Martin M, Brasiuniene B, Donnelly C, Liu X, Thomes Pepin J, de la Garza J, Wang K, Contreras Mejia F, Sehouli J, Klasa-Mazurkiewicz D, Del Rosario PM, Van Nieuwenhuysen E, DUO-E Investigators. Durvalumab Plus Carboplatin/Paclitaxel Followed by Maintenance Durvalumab With or Without Olaparib as First-Line Treatment for Advanced Endometrial Cancer: The Phase III DUO-E Trial. J Clin Oncol. 2024 Jan 20; 42(3):283-299. PMID: 37864337; PMCID: PMC10824389.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    24. Grisham RN, Slomovitz BM, Andrews N, Banerjee S, Brown J, Carey MS, Chui H, Coleman RL, Fader AN, Gaillard S, Gourley C, Sood AK, Monk BJ, Moore KN, Ray-Coquard I, Shih IM, Westin SN, Wong KK, Gershenson DM. Low-grade serous ovarian cancer: expert consensus report on the state of the science. Int J Gynecol Cancer. 2023 09 04; 33(9):1331-1344. PMID: 37591609; PMCID: PMC10511962.
      Citations:    Fields:    Translation:Humans
    25. Nasioudis D, Fernandez ML, Wong N, Powell DJ, Mills GB, Westin S, Fader AN, Carey MS, Simpkins F. The spectrum of MAPK-ERK pathway genomic alterations in gynecologic malignancies: Opportunities for novel therapeutic approaches. Gynecol Oncol. 2023 Oct; 177:86-94. PMID: 37657193.
      Citations:    Fields:    
    26. Zhang X, Yao J, Li X, Niu N, Liu Y, Hajek RA, Peng G, Westin S, Sood AK, Liu J. Targeting polyploid giant cancer cells potentiates a therapeutic response and overcomes resistance to PARP inhibitors in ovarian cancer. Sci Adv. 2023 07 21; 9(29):eadf7195. PMID: 37478190; PMCID: PMC10361597.
      Citations: 6     Fields:    Translation:HumansCells
    27. Morris VK, Jazaeri A, Westin SN, Pettaway C, George S, Huey RW, Grinsfelder M, Shafer A, Johnson B, Vining D, Guo M, Fellman B, Frumovitz M. Phase II Trial of MEDI0457 and Durvalumab for Patients With Recurrent/Metastatic Human Papillomavirus-Associated Cancers. Oncologist. 2023 07 05; 28(7):618-623. PMID: 37104874; PMCID: PMC10322132.
      Citations: 4     Fields:    Translation:HumansCellsCTClinical Trials
    28. Konski A, Deshmukh S, Klopp AH, Yeung AR, Westin SN, Thompson JS, Doncals DE, Cantuaria GHC, D'Souza DP, Chang A, Kundapur V, Mohan DS, Haas ML, Kim YB, Ferguson CL, Pugh SL, Kachnic LA, Bruner DW. Quality-adjusted survival in women with gynecologic malignancies receiving IMRT after surgery: A Ppatient Rreported Ooutcome study of NRG oncology's RTOG 1203. Gynecol Oncol. 2023 08; 175:176-181. PMID: 37393743; PMCID: PMC10527270.
      Citations:    Fields:    Translation:Humans
    29. Leo J, Dondossola E, Basham KJ, Wilson NR, Alhalabi O, Gao J, Kurnit KC, White MG, McQuade JL, Westin SN, Wellberg EA, Frigo DE. Stranger Things: New Roles and Opportunities for Androgen Receptor in Oncology Beyond Prostate Cancer. Endocrinology. 2023 04 17; 164(6). PMID: 37154098; PMCID: PMC10413436.
      Citations:    Fields:    Translation:HumansCells
    30. Almanza-Huante E, Bataller A, Urrutia S, Gener-Ricos G, Briski RE, Kanagal-Shamanna R, Lu KH, Westin SN, Yap TA, Takahashi K, Ravandi F, Alvarado Y, Kadia T, Sasaki K, Kantarjian HM, Garcia-Manero G. Outcomes of patients with therapy-related myeloid neoplasms after treatment with poly(ADP-ribose) polymerase proteins inhibitors for solid tumours. Br J Haematol. 2023 05; 201(3):e25-e29. PMID: 36951293.
      Citations:    Fields:    Translation:Humans
    31. Foster KI, Shaw KRM, Jin J, Westin SN, Yap TA, Glassman DM, Jazaeri AA, Rauh-Hain JA, Lee S, Fellman BM, Ju Z, Liu Y, Fleming ND, Sood AK. Clinical implications of tumor-based next-generation sequencing in high-grade epithelial ovarian cancer. Cancer. 2023 06 01; 129(11):1672-1680. PMID: 36930815.
      Citations:    Fields:    Translation:Humans
    32. Foster KI, Flores Legarreta A, Kamat R, Handley KF, Glassman D, How JA, Lawson BC, Westin SN, Ramondetta LM, Frumovitz M, Gershenson DM, Sood AK, Hillman RT. Clinical outcomes of leuprolide acetate in the treatment of recurrent ovarian granulosa cell tumors. Am J Obstet Gynecol. 2023 06; 228(6):724.e1-724.e9. PMID: 36907533; PMCID: PMC10247505.
      Citations:    Fields:    Translation:Humans
    33. Dasari SK, Joseph R, Umamaheswaran S, Mangala LS, Bayraktar E, Rodriguez-Aguayo C, Wu Y, Nguyen N, Powell RT, Sobieski M, Liu Y, Chowdhury MA, Amero P, Stephan C, Lopez-Berestein G, Westin SN, Sood AK. Combination of EphA2- and Wee1-Targeted Therapies in Endometrial Cancer. Int J Mol Sci. 2023 Feb 15; 24(4). PMID: 36835335; PMCID: PMC9962847.
      Citations: 1     Fields:    Translation:HumansAnimalsCells
    34. Glassman D, Kim MS, Spradlin M, Badal S, Taki M, Bhattacharya P, Dutta P, Kingsley CV, Foster KI, Animasahun O, Jeon JH, Achreja A, Jayaraman A, Kumar P, Nenwani M, Wuchu F, Bayraktar E, Wu Y, Stur E, Mangala L, Lee S, Yap TA, Westin SN, Eberlin LS, Nagrath D, Sood AK. Exploiting metabolic vulnerabilities after anti-VEGF antibody therapy in ovarian cancer. iScience. 2023 Feb 17; 26(2):106020. PMID: 36824283; PMCID: PMC9941132.
      Citations:    
    35. Son J, Lin HY, Fu S, Biter AB, Dumbrava EE, Karp DD, Naing A, Pant S, Piha-Paul SA, Rodon J, Subbiah V, Tsimberidou AM, Yap TA, Frumovitz MM, Jazaeri AA, Ramirez PT, Westin SN, Yuan Y, Meric-Bernstam F, Hong DS. Predictors of Oncologic Outcome in Patients Receiving Phase I Investigational Therapy for Recurrent or Metastatic Cervical Cancer. J Immunother Precis Oncol. 2023 Feb; 6(1):10-18. PMID: 36751659; PMCID: PMC9888522.
      Citations:    
    36. Pham MM, Avila M, Hinchcliff E, Westin SN. Clinical Application of Poly(ADP-Ribose) Polymerase (PARP) Inhibitors in Ovarian Cancer. Cancer Treat Res. 2023; 186:71-89. PMID: 37978131.
      Citations:    Fields:    Translation:Humans
    37. Vellano CP, White MG, Andrews MC, Chelvanambi M, Witt RG, Daniele JR, Titus M, McQuade JL, Conforti F, Burton EM, Lastrapes MJ, Ologun G, Cogdill AP, Morad G, Prieto P, Lazar AJ, Chu Y, Han G, Khan MAW, Helmink B, Davies MA, Amaria RN, Kovacs JJ, Woodman SE, Patel S, Hwu P, Peoples M, Lee JE, Cooper ZA, Zhu H, Gao G, Banerjee H, Lau M, Gershenwald JE, Lucci A, Keung EZ, Ross MI, Pala L, Pagan E, Segura RL, Liu Q, Borthwick MS, Lau E, Yates MS, Westin SN, Wani K, Tetzlaff MT, Haydu LE, Mahendra M, Ma X, Logothetis C, Kulstad Z, Johnson S, Hudgens CW, Feng N, Federico L, Long GV, Futreal PA, Arur S, Tawbi HA, Moran AE, Wang L, Heffernan TP, Marszalek JR, Wargo JA. Author Correction: Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy. Nature. 2023 Jan; 613(7945):E3. PMID: 36627494.
      Citations:    Fields:    
    38. Fu S, Yao S, Yuan Y, Previs RA, Elias AD, Carvajal RD, George TJ, Yuan Y, Yu L, Westin SN, Xing Y, Dumbrava EE, Karp DD, Piha-Paul SA, Tsimberidou AM, Ahnert JR, Takebe N, Lu K, Keyomarsi K, Meric-Bernstam F. Multicenter Phase II Trial of the WEE1 Inhibitor Adavosertib in Refractory Solid Tumors Harboring CCNE1 Amplification. J Clin Oncol. 2023 03 20; 41(9):1725-1734. PMID: 36469840; PMCID: PMC10489509.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    39. Westin SN, Fu S, Tsimberidou A, Piha-Paul S, Akhmedzhanov F, Yilmaz B, McQuinn L, Brink AL, Gong J, Leung CH, Lin H, Hong DS, Pant S, Carter B, Jazaeri A, Gershenson D, Sood AK, Coleman RL, Shah J, Meric-Bernstam F, Naing A. Selinexor in combination with weekly paclitaxel in patients with metastatic solid tumors: Results of an open label, single-center, multi-arm phase 1b study with expansion phase in ovarian cancer. Gynecol Oncol. 2023 01; 168:76-82. PMID: 36423446; PMCID: PMC9797438.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    40. Avila M, Grinsfelder MO, Pham M, Westin SN. Targeting the PI3K Pathway in Gynecologic Malignancies. Curr Oncol Rep. 2022 12; 24(12):1669-1676. PMID: 36401704; PMCID: PMC10862662.
      Citations:    Fields:    Translation:Humans
    41. Chu YY, Chen MK, Wei Y, Lee HH, Xia W, Wang YN, Yam C, Hsu JL, Wang HL, Chang WC, Yamaguchi H, Jiang Z, Liu C, Li CF, Nie L, Chan LC, Gao Y, Wang SC, Liu J, Westin SN, Lee S, Sood AK, Yang L, Hortobagyi GN, Yu D, Hung MC. Targeting the ALK-CDK9-Tyr19 kinase cascade sensitizes ovarian and breast tumors to PARP inhibition via destabilization of the P-TEFb complex. Nat Cancer. 2022 10; 3(10):1211-1227. PMID: 36253486; PMCID: PMC9586872.
      Citations: 1     Fields:    Translation:HumansAnimals
    42. Kurnit KC, Nobre SP, Fellman BM, Iglesias DA, Lindemann K, Jhingran A, Eriksson AGZ, Ataseven B, Glaser GE, Mueller JJ, Westin SN, Soliman PT. Adjuvant therapy in women with early stage uterine serous carcinoma: A multi-institutional study. Gynecol Oncol. 2022 Dec; 167(3):452-457. PMID: 36243601; PMCID: PMC10278585.
      Citations:    Fields:    Translation:Humans
    43. Handley KF, Sims TT, Bateman NW, Glassman D, Foster KI, Lee S, Yao J, Yao H, Fellman BM, Liu J, Lu Z, Conrads KA, Hood BL, Barakat W, Zhao L, Zhang J, Westin SN, Celestino J, Rangel KM, Badal S, Pereira I, Ram PT, Maxwell GL, Eberlin LS, Futreal PA, Bast RC, Fleming ND, Conrads TP, Sood AK. Classification of High-Grade Serous Ovarian Cancer Using Tumor Morphologic Characteristics. JAMA Netw Open. 2022 10 03; 5(10):e2236626. PMID: 36239936; PMCID: PMC9568802.
      Citations: 2     Fields:    Translation:HumansCells
    44. Gershenson DM, Cobb LP, Westin SN, Zhang Y, Jazaeri A, Malpica A, Sun CC. Contemporary primary treatment of women with stage II-IV low-grade serous ovarian/peritoneal cancer (LGSOC): Determinants of relapse and disease-free survival. Gynecol Oncol. 2022 11; 167(2):139-145. PMID: 36137845.
      Citations:    
    45. Yeung AR, Deshmukh S, Klopp AH, Gil KM, Wenzel L, Westin SN, Konski AA, Gaffney DK, Small W, Thompson JS, Doncals DE, Cantuaria GHC, D'Souza DP, Chang A, Kundapur V, Mohan DS, Haas ML, Kim YB, Ferguson CL, Pugh SL, Kachnic LA, Bruner DW. Intensity-Modulated Radiation Therapy Reduces Patient-Reported Chronic Toxicity Compared With Conventional Pelvic Radiation Therapy: Updated Results of a Phase III Trial. J Clin Oncol. 2022 09 20; 40(27):3115-3119. PMID: 35960897; PMCID: PMC9851703.
      Citations:    
    46. Zhao L, Corvigno S, Ma S, Celestino J, Fleming ND, Hajek RA, Lankenau Ahumada A, Jennings NB, Thompson EJ, Tang H, Westin SN, Jazaeri AA, Zhang J, Futreal PA, Sood AK, Lee S. Molecular Profiles of Serum-Derived Extracellular Vesicles in High-Grade Serous Ovarian Cancer. Cancers (Basel). 2022 Jul 23; 14(15). PMID: 35892848; PMCID: PMC9330879.
      Citations:    
    47. Ngoi NYL, Westin SN, Yap TA. Targeting the DNA damage response beyond poly(ADP-ribose) polymerase inhibitors: novel agents and rational combinations. Curr Opin Oncol. 2022 09 01; 34(5):559-569. PMID: 35787597; PMCID: PMC9371461.
      Citations:    Fields:    
    48. Vellano CP, White MG, Andrews MC, Chelvanambi M, Witt RG, Daniele JR, Titus M, McQuade JL, Burton EM, Lastrapes MJ, Ologun G, Cogdill AP, Morad G, Prieto P, Lazar AJ, Chu Y, Han G, Khan MAW, Helmink B, Davies MA, Amaria RN, Kovacs JJ, Woodman SE, Patel S, Hwu P, Peoples M, Lee JE, Cooper ZA, Zhu H, Gao G, Banerjee H, Lau M, Gershenwald JE, Lucci A, Keung EZ, Ross MI, Pagan E, Segura RL, Liu Q, Borthwick MS, Lau E, Yates MS, Westin SN, Wani K, Tetzlaff MT, Haydu LE, Mahendra M, Ma X, Logothetis C, Kulstad Z, Johnson S, Hudgens CW, Feng N, Federico L, Long GV, Futreal PA, Arur S, Tawbi HA, Moran AE, Wang L, Heffernan TP, Marszalek JR, Wargo JA, Conforti F, Pala L. Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy. Nature. 2022 06; 606(7915):797-803. PMID: 35705814; PMCID: PMC10071594.
      Citations: 1     Fields:    Translation:HumansAnimals
    49. Monk BJ, Parkinson C, Lim MC, O'Malley DM, Oaknin A, Wilson MK, Coleman RL, Lorusso D, Bessette P, Ghamande S, Christopoulou A, Prendergast E, Demirkiran F, Mikheeva O, Yeku O, Chudecka-Glaz A, Schenker M, Littell RD, Safra T, Chou HH, Morgan MA, Barlin JN, Van Gorp T, Ueland F, Lindahl G, Anderson C, Collins DC, Moore K, Marme F, Westin SN, McNeish IA, Shih D, Lin KK, Goble S, Hume S, Fujiwara K, Kristeleit RS, Provencher D, Droch?tek V. A Randomized, Phase III Trial to Evaluate Rucaparib Monotherapy as Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer (ATHENA-MONO/GOG-3020/ENGOT-ov45). J Clin Oncol. 2022 12 01; 40(34):3952-3964. PMID: 35658487; PMCID: PMC9746782.
      Citations:    Fields:    
    50. Handley KF, Sood AK, Molin GZD, Westin SN, Meyer LA, Fellman B, Soliman PT, Coleman RL, Fleming ND. Frailty repels the knife: The impact of frailty index on surgical intervention and outcomes. Gynecol Oncol. 2022 07; 166(1):50-56. PMID: 35599168.
      Citations:    Fields:    Translation:Humans
    51. Hinchcliff E, Westin SN, Herzog TJ. State of the science: Contemporary front-line treatment of advanced ovarian cancer. Gynecol Oncol. 2022 07; 166(1):18-24. PMID: 35589433.
      Citations:    Fields:    Translation:Humans
    52. Kim ST, Chu Y, Misoi M, Suarez-Almazor ME, Tayar JH, Lu H, Buni M, Kramer J, Rodriguez E, Hussain Z, Neelapu SS, Wang J, Shah AY, Tannir NM, Campbell MT, Gibbons DL, Cascone T, Lu C, Blumenschein GR, Altan M, Lim B, Valero V, Loghin ME, Tu J, Westin SN, Naing A, Garcia-Manero G, Abdel-Wahab N, Tawbi HA, Hwu P, Oliva ICG, Davies MA, Patel SP, Zou J, Futreal A, Diab A, Wang L, Nurieva R. Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy. Nat Commun. 2022 04 12; 13(1):1970. PMID: 35413951; PMCID: PMC9005525.
      Citations: 1     Fields:    Translation:HumansCells
    53. Westin SN. Should secondary cytoreduction be used in recurrent ovarian cancer? Clin Adv Hematol Oncol. 2022 04; 20(4):215-217. PMID: 35389385.
      Citations:    Fields:    Translation:Humans
    54. Stover EH, Xiong N, Myers AP, Tayob N, Engvold V, Polak M, Broaddus RR, Makker V, Drapkin R, Liu JF, Horowitz NS, Meric-Bernstam F, Aghajanian C, Coleman RL, Mills GB, Cantley LC, Matulonis UA, Westin SN, Konstantinopoulos PA. A phase II study of MK-2206, an AKT inhibitor, in uterine serous carcinoma. Gynecol Oncol Rep. 2022 Apr; 40:100974. PMID: 35434236; PMCID: PMC9011027.
      Citations:    
    55. Gershenson DM, Sun CC, Westin SN, Eyada M, Cobb LP, Nathan LC, Sood AK, Malpica A, Hillman RT, Wong KK. The genomic landscape of low-grade serous ovarian/peritoneal carcinoma and its impact on clinical outcomes. Gynecol Oncol. 2022 06; 165(3):560-567. PMID: 35606067.
      Citations:    Fields:    Translation:Humans
    56. LaFargue CJ, Handley KF, Fleming ND, Nick AM, Chelariu-Raicu A, Fellman B, Castellano T, Ogasawara A, Hom-Tedla M, Blake EA, da Costa AABA, Crim AK, Rauh-Hain A, Westin SN, Coleman RL, Matsuo K, Baiocchi G, Hasegawa K, Moore K, Sood AK. Clinical analysis of pathologic complete responders in advanced-stage ovarian cancer. Gynecol Oncol. 2022 04; 165(1):82-89. PMID: 35216808; PMCID: PMC8969169.
      Citations:    Fields:    Translation:Humans
    57. Wu Y, Jennings NB, Sun Y, Dasari SK, Bayraktar E, Corvigno S, Stur E, Glassman D, Mangala LS, Lankenau Ahumada A, Westin SN, Sood AK, Hu W. Targeting CCR2+ macrophages with BET inhibitor overcomes adaptive resistance to anti-VEGF therapy in ovarian cancer. J Cancer Res Clin Oncol. 2022 Apr; 148(4):803-821. PMID: 35094142; PMCID: PMC8930900.
      Citations: 1     Fields:    Translation:HumansAnimalsCells
    58. Makker V, MacKay H, Ray-Coquard I, Levine DA, Westin SN, Aoki D, Oaknin A. Endometrial cancer. Nat Rev Dis Primers. 2021 12 09; 7(1):88. PMID: 34887451; PMCID: PMC9421940.
      Citations: 3     Fields:    Translation:Humans
    59. Pham MM, Hinchcliff E, Avila M, Westin SN. The Clinical Challenges, Trials, and Errors of Combatting Poly(ADP-Ribose) Polymerase Inhibitors Resistance. Cancer J. 2021 Nov-Dec 01; 27(6):491-500. PMID: 34904812; PMCID: PMC9255699.
      Citations:    Fields:    Translation:HumansCells
    60. Hinchcliff EM, Westin SN. Next generation sequencing for gynecologic malignancy: Promise and potential pitfalls. Gynecol Oncol. 2021 11; 163(2):217-219. PMID: 34756289.
      Citations: 1     Fields:    Translation:Humans
    61. Monk BJ, Coleman RL, Fujiwara K, Wilson MK, Oza AM, Oaknin A, O'Malley DM, Westin SN, Safra T, Herzog TJ, N Eskander R, Lin KK, Shih D, Goble S, Grechko N, Hume S, Maloney L, McNeish IA, Kristeleit RS, Lorusso D, Marm? F. ATHENA (GOG-3020/ENGOT-ov45): a randomized, phase III trial to evaluate rucaparib as monotherapy (ATHENA-MONO) and rucaparib in combination with nivolumab (ATHENA-COMBO) as maintenance treatment following frontline platinum-based chemotherapy in ovarian cancer. Int J Gynecol Cancer. 2021 12; 31(12):1589-1594. PMID: 34593565; PMCID: PMC8666815.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    62. Handley KF, Rodriguez-Aguayo C, Ma S, Stur E, Joseph R, Bayraktar E, Dasari SK, Nguyen N, Powell RT, Sobieski M, Ivan C, Kim M, Umamaheswaran S, Glassman D, Wen Y, Amero P, Stephan C, Coleman RL, Landesman Y, Westin SN, Ram PT, Sood AK. Rational Combination of CRM1 Inhibitor Selinexor and Olaparib Shows Synergy in Ovarian Cancer Cell Lines and Mouse Models. Mol Cancer Ther. 2021 12; 20(12):2352-2361. PMID: 34583979; PMCID: PMC8643313.
      Citations:    Fields:    Translation:HumansAnimalsCells
    63. Westin SN, Labrie M, Litton JK, Blucher A, Fang Y, Vellano CP, Marszalek JR, Feng N, Ma X, Creason A, Fellman B, Yuan Y, Lee S, Kim TB, Liu J, Chelariu-Raicu A, Chen TH, Kabil N, Soliman PT, Frumovitz M, Schmeler KM, Jazaeri A, Lu KH, Murthy R, Meyer LA, Sun CC, Sood AK, Coleman RL, Mills GB. Phase Ib Dose Expansion and Translational Analyses of Olaparib in Combination with Capivasertib in Recurrent Endometrial, Triple-Negative Breast, and Ovarian Cancer. Clin Cancer Res. 2021 12 01; 27(23):6354-6365. PMID: 34518313; PMCID: PMC8639651.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    64. Corvigno S, Burks JK, Hu W, Zhong Y, Jennings NB, Fleming ND, Westin SN, Fellman B, Liu J, Sood AK. Immune microenvironment composition in high-grade serous ovarian cancers based on BRCA mutational status. J Cancer Res Clin Oncol. 2021 Dec; 147(12):3545-3555. PMID: 34476576; PMCID: PMC8557133.
      Citations: 2     Fields:    Translation:HumansCells
    65. Westin SN, Louie-Gao M, Gupta D, Thaker PH. Risk factors for progression or death after first-line platinum-based chemotherapy in real-world patients in the?USA with ovarian cancer from 2011 to 2018. Future Oncol. 2021 Nov; 17(32):4263-4274. PMID: 34378405.
      Citations:    Fields:    Translation:Humans
    66. Alvarez Secord A, O'Malley DM, Sood AK, Westin SN, Liu JF. Rationale for combination PARP inhibitor and antiangiogenic treatment in advanced epithelial ovarian cancer: A review. Gynecol Oncol. 2021 08; 162(2):482-495. PMID: 34090705.
      Citations: 3     Fields:    Translation:HumansCells
    67. How JA, Patel S, Fellman B, Lu KH, Hwu P, Ramondetta LM, Westin SN, Fleming ND, Soliman PT, Jazaeri AA. Toxicity and efficacy of the combination of pembrolizumab with recommended or reduced starting doses of lenvatinib for treatment of recurrent endometrial cancer. Gynecol Oncol. 2021 07; 162(1):24-31. PMID: 33958211; PMCID: PMC8222164.
      Citations: 3     Fields:    Translation:Humans
    68. Fleming ND, Westin SN, Rauh-Hain JA, Soliman PT, Fellman BM, Coleman RL, Meyer LA, Shafer A, Cobb LP, Jazaeri A, Lu KH, Sood AK. Factors associated with response to neoadjuvant chemotherapy in advanced stage ovarian cancer. Gynecol Oncol. 2021 07; 162(1):65-71. PMID: 33838925; PMCID: PMC8287765.
      Citations: 1     Fields:    Translation:Humans
    69. Yao S, Janku F, Subbiah V, Stewart J, Patel SP, Kaseb A, Westin SN, Naing A, Tsimberidou AM, Hong D, Piha-Paul SA, Shi N, Johnston A, Bomalaski J, Fu S. Phase 1 trial of ADI-PEG20 plus cisplatin in patients with pretreated metastatic melanoma or other advanced solid malignancies. Br J Cancer. 2021 04; 124(9):1533-1539. PMID: 33674736; PMCID: PMC8076217.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    70. Zhong Y, Liu J, Li X, Westin SN, Malpica A, Lawson BC, Lee S, Fellman BM, Coleman RL, Sood AK, Fleming ND. A Modified 2 Tier Chemotherapy Response Score (CRS) and Other Histopathologic Features for Predicting Outcomes of Patients with Advanced Extrauterine High-Grade Serous Carcinoma after Neoadjuvant Chemotherapy. Cancers (Basel). 2021 Feb 09; 13(4). PMID: 33572451; PMCID: PMC7916221.
      Citations: 2     
    71. Siedel JH, Ring KL, Hu W, Dood RL, Wang Y, Baggerly K, Darcy KM, Conrads TP, Gallagher S, Tshiaba P, Neff C, Timms KM, Mangala S, Westin SN, Broaddus R, Lopez-Berestein G, Lu KH, Coleman RL, Maxwell GL, Sood AK. Clinical significance of homologous recombination deficiency score testing in endometrial Cancer. Gynecol Oncol. 2021 03; 160(3):777-785. PMID: 33563487; PMCID: PMC8538374.
      Citations: 4     Fields:    Translation:Humans
    72. Coleman RL, Hu W, Soliman P, Nick A, Ramirez PT, Westin SN, Garcia ME, Zhu Z, Palancia J, Fellman BM, Yuan Y, Ram P, Bischoff F, Schmeler K, Bodurka D, Meyer LA, Sood AK. Dasatinib, paclitaxel, and carboplatin in women with advanced-stage or recurrent endometrial cancer: A pilot clinical and translational study. Gynecol Oncol. 2021 04; 161(1):104-112. PMID: 33551196.
      Citations: 1     Fields:    Translation:HumansCellsCTClinical Trials
    73. Hinchcliff E, Chelariu-Raicu A, Westin SN. Current and future landscape of poly (ADP-ribose) polymerase inhibition resistance. Curr Opin Obstet Gynecol. 2021 02 01; 33(1):19-25. PMID: 33315700; PMCID: PMC7958870.
      Citations:    Fields:    Translation:Humans
    74. Harrison RF, Cantor SB, Sun CC, Villanueva M, Westin SN, Fleming ND, Toumazis I, Sood AK, Lu KH, Meyer LA. Cost-effectiveness of laparoscopic disease assessment in patients with newly diagnosed advanced ovarian cancer. Gynecol Oncol. 2021 04; 161(1):56-62. PMID: 33536126; PMCID: PMC8247119.
      Citations:    Fields:    Translation:Humans
    75. Lee S, Zhao L, Little LD, Westin SN, Jazarei AA, Fleming ND, Zhang J, Futreal PA, Sood AK. Distinct T?cell receptor repertoire diversity of clinically defined high-grade serous ovarian cancer treatment subgroups. iScience. 2021 Feb 19; 24(2):102053. PMID: 33537658; PMCID: PMC7840469.
      Citations: 2     
    76. How JA, Jazaeri A, Westin SN, Sood AK, Ramondetta LM, Xu M, Abonofal A, Karp DD, Subbiah V, Stephen B, Rodon JA, Yang F, Naing A. The clinical efficacy and safety of single-agent pembrolizumab in patients with recurrent granulosa cell tumors of the ovary: a case series from a phase II basket trial. Invest New Drugs. 2021 06; 39(3):829-835. PMID: 33415580; PMCID: PMC8076052.
      Citations: 2     Fields:    Translation:HumansCellsCTClinical Trials
    77. Zhukovsky DS, Haider A, Williams JL, Naqvi S, Joshi N, Mills S, Soliman PT, Mathew B, Bodurka D, Meyer LA, Westin S, Frumovitz M, Nowitz MB, Archie L, Fenton S, Lang K, Boving V, Bruera E. An Integrated Approach to Selecting a Prepared Medical Decision-Maker. J Pain Symptom Manage. 2021 06; 61(6):1305-1310. PMID: 33348030.
      Citations:    Fields:    Translation:Humans
    78. Fleming ND, Westin SN, Meyer LA, Shafer A, Rauh-Hain JA, Onstad M, Cobb L, Bevers M, Fellman BM, Burzawa J, Bhosale P, Zand B, Jazaeri A, Levenback C, Coleman RL, Soliman PT, Sood AK. Correlation of surgeon radiology assessment with laparoscopic disease site scoring in patients with advanced ovarian cancer. Int J Gynecol Cancer. 2021 01; 31(1):92-97. PMID: 33154095; PMCID: PMC8266398.
      Citations: 1     Fields:    Translation:Humans
    79. Bailey CD, Previs R, Fellman BM, Zaid T, Huang M, Brown A, Enbaya A, Balakrishnan N, Broaddus RR, Bodurka DC, Soliman P, Fleming ND, Nick A, Sood AK, Westin SN. Pathologic distribution at the time of interval tumor reductive surgery informs personalized surgery for high-grade ovarian cancer. Int J Gynecol Cancer. 2021 02; 31(2):232-237. PMID: 33122243; PMCID: PMC8263077.
      Citations:    Fields:    Translation:Humans
    80. Onstad M, Coleman RL, Westin SN. Movement of Poly-ADP Ribose (PARP) Inhibition into Frontline Treatment of Ovarian Cancer. Drugs. 2020 Oct; 80(15):1525-1535. PMID: 32852746; PMCID: PMC7541632.
      Citations: 1     Fields:    Translation:HumansCells
    81. Stewart KI, Yates MS, Westin SN. Pushing the envelope: expanding fertility sparing treatment of endometrial cancer. J Gynecol Oncol. 2020 09; 31(5):e82. PMID: 32808503; PMCID: PMC7440981.
      Citations: 2     Fields:    Translation:Humans
    82. Westin SN, Fellman B, Sun CC, Broaddus RR, Woodall ML, Pal N, Urbauer DL, Ramondetta LM, Schmeler KM, Soliman PT, Fleming ND, Burzawa JK, Nick AM, Milbourne AM, Yuan Y, Lu KH, Bodurka DC, Coleman RL, Yates MS. Prospective phase II trial of levonorgestrel intrauterine device: nonsurgical approach for complex atypical hyperplasia and early-stage endometrial cancer. Am J Obstet Gynecol. 2021 02; 224(2):191.e1-191.e15. PMID: 32805208; PMCID: PMC7855308.
      Citations: 13     Fields:    Translation:HumansCellsCTClinical Trials
    83. Tew WP, Lacchetti C, Ellis A, Maxian K, Banerjee S, Bookman M, Jones MB, Lee JM, Liu JF, Moore KN, Muller C, Rodriguez P, Walsh C, Westin SN, Kohn EC, Lheureux S. PARP Inhibitors in the Management of Ovarian Cancer: ASCO Guideline. J Clin Oncol. 2020 10 20; 38(30):3468-3493. PMID: 32790492; PMCID: PMC8942301.
      Citations: 40     Fields:    Translation:Humans
    84. Cobb LP, Sun CC, Iyer R, Nick AM, Fleming ND, Westin SN, Sood AK, Wong KK, Silva EG, Gershenson DM. The role of neoadjuvant chemotherapy in the management of low-grade serous carcinoma of the ovary and peritoneum: Further evidence of relative chemoresistance. Gynecol Oncol. 2020 09; 158(3):653-658. PMID: 32709538.
      Citations: 4     Fields:    Translation:Humans
    85. Obermair A, Baxter E, Brennan DJ, McAlpine JN, Muellerer JJ, van Gent MDJM, Coleman RL, Westin SN, Yates MS, Krakstad C, Janda M, Amant F. Fertility-sparing treatment in early endometrial cancer: current state and future strategies. Obstet Gynecol Sci. 2020 Jul; 63(4):417-431. PMID: 32689770; PMCID: PMC7393748.
      Citations: 11     
    86. Hinchcliff EM, Meyer LA, Westin SN. Has dose-dense chemotherapy met an ICONic end? Lancet Oncol. 2020 07; 21(7):869-870. PMID: 32615101; PMCID: PMC8284846.
      Citations: 1     Fields:    Translation:Humans
    87. Frumovitz M, Westin SN, Salvo G, Zarifa A, Xu M, Yap TA, Rodon AJ, Karp DD, Abonofal A, Jazaeri AA, Naing A. Phase II study of pembrolizumab efficacy and safety in women with recurrent small cell neuroendocrine carcinoma of the lower genital tract. Gynecol Oncol. 2020 09; 158(3):570-575. PMID: 32534809; PMCID: PMC7486997.
      Citations: 13     Fields:    Translation:HumansCTClinical Trials
    88. Kim KH, Moore KN, Arend RC, Bakkum-Gamez JN, Westin SN. The 2020 SGO Annual Meeting Report. Gynecol Oncol. 2020 07; 158(1):12-15. PMID: 32487447.
      Citations: 1     Fields:    Translation:Humans
    89. Kurnit KC, Avila M, Hinchcliff EM, Coleman RL, Westin SN. PARP inhibition in the ovarian cancer patient: Current approvals and future directions. Pharmacol Ther. 2020 09; 213:107588. PMID: 32450190; PMCID: PMC8331065.
      Citations: 4     Fields:    Translation:Humans
    90. Baxter E, Brennan DJ, McAlpine JN, Mueller JJ, van Gent MDJM, Huntsman DG, Coleman RL, Westin SN, Yates MS, Krakstad C, Quinn MA, Janda M, Obermair A, Amant F. Improving response to progestin treatment of low-grade endometrial cancer. Int J Gynecol Cancer. 2020 11; 30(11):1811-1823. PMID: 32381512; PMCID: PMC8445150.
      Citations: 6     Fields:    Translation:Humans
    91. Kurnit KC, Westin SN. Slow and steady wins the race: precision medicine for low risk endometrial cancer. Int J Gynecol Cancer. 2020 06; 30(6):724-725. PMID: 32376741.
      Citations:    Fields:    Translation:Humans
    92. Pothuri B, Alvarez Secord A, Armstrong DK, Chan J, Fader AN, Huh W, Kesterson J, Liu JF, Moore K, Westin SN, Naumann RW. Anti-cancer therapy and clinical trial considerations for gynecologic oncology patients during the COVID-19 pandemic crisis. Gynecol Oncol. 2020 07; 158(1):16-24. PMID: 32386911; PMCID: PMC7177100.
      Citations: 16     Fields:    Translation:HumansPHPublic Health
    93. Lee S, Zhao L, Rojas C, Bateman NW, Yao H, Lara OD, Celestino J, Morgan MB, Nguyen TV, Conrads KA, Rangel KM, Dood RL, Hajek RA, Fawcett GL, Chu RA, Wilson K, Loffredo JL, Viollet C, Jazaeri AA, Dalgard CL, Mao X, Song X, Zhou M, Hood BL, Banskota N, Wilkerson MD, Te J, Soltis AR, Roman K, Dunn A, Cordover D, Eterovic AK, Liu J, Burks JK, Baggerly KA, Fleming ND, Lu KH, Westin SN, Coleman RL, Mills GB, Casablanca Y, Zhang J, Conrads TP, Maxwell GL, Futreal PA, Sood AK. Molecular Analysis of Clinically Defined Subsets of High-Grade Serous Ovarian Cancer. Cell Rep. 2020 04 14; 31(2):107502. PMID: 32294438; PMCID: PMC7234854.
      Citations: 26     Fields:    Translation:Humans
    94. Abu-Sbeih H, Mallepally N, Goldstein R, Chen E, Tang T, Dike UK, Al-Asadi M, Westin S, Halperin D, Wang Y. Gastrointestinal toxic effects in patients with cancer receiving platinum-based therapy. J Cancer. 2020; 11(11):3144-3150. PMID: 32231718; PMCID: PMC7097936.
      Citations: 3     
    95. Yeung AR, Pugh SL, Klopp AH, Gil KM, Wenzel L, Westin SN, Gaffney DK, Small W, Thompson S, Doncals DE, Cantuaria GHC, Yaremko BP, Chang A, Kundapur V, Mohan DS, Haas ML, Kim YB, Ferguson CL, Deshmukh S, Bruner DW, Kachnic LA. Improvement in Patient-Reported Outcomes With Intensity-Modulated Radiotherapy (RT) Compared With Standard RT: A Report From the NRG Oncology RTOG 1203 Study. J Clin Oncol. 2020 05 20; 38(15):1685-1692. PMID: 32073955; PMCID: PMC7238486.
      Citations: 18     Fields:    Translation:HumansCTClinical Trials
    96. Arend R, Westin SN, Coleman RL. Decision analysis for secondline maintenance treatment of platinum sensitive recurrent ovarian cancer: a review. Int J Gynecol Cancer. 2020 05; 30(5):684-694. PMID: 32079709.
      Citations: 2     Fields:    Translation:HumansCells
    97. Berg HF, Ju Z, Myrvold M, Fasmer KE, Halle MK, Hoivik EA, Westin SN, Trovik J, Haldorsen IS, Mills GB, Krakstad C, Werner HMJ. Development of prediction models for lymph node metastasis in endometrioid endometrial carcinoma. Br J Cancer. 2020 03; 122(7):1014-1022. PMID: 32037399; PMCID: PMC7109044.
      Citations: 2     Fields:    Translation:Humans
    98. Markham MJ, Wachter K, Agarwal N, Bertagnolli MM, Chang SM, Dale W, Diefenbach CSM, Rodriguez-Galindo C, George DJ, Gilligan TD, Harvey RD, Johnson ML, Kimple RJ, Knoll MA, LoConte N, Maki RG, Meisel JL, Meyerhardt JA, Pennell NA, Rocque GB, Sabel MS, Schilsky RL, Schneider BJ, Tap WD, Uzzo RG, Westin SN. Clinical Cancer Advances 2020: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. J Clin Oncol. 2020 04 01; 38(10):1081. PMID: 32013670.
      Citations: 34     Fields:    Translation:Humans
    99. Stewart KI, Eska JS, Harrison RF, Suidan R, Abraham A, Chisholm GB, Meyer LA, Westin SN, Fleming ND, Frumovitz M, Aloia TA, Soliman PT. Implementation of a sentinel lymph node mapping algorithm for endometrial cancer: surgical outcomes and hospital charges. Int J Gynecol Cancer. 2020 03; 30(3):352-357. PMID: 31911539; PMCID: PMC7322720.
      Citations: 4     Fields:    Translation:Humans
    100. Lakomy DS, Urbauer DL, Westin SN, Lin LL. Phase I study of the PARP inhibitor talazoparib with radiation therapy for locally recurrent gynecologic cancers. Clin Transl Radiat Oncol. 2020 Mar; 21:56-61. PMID: 31993510; PMCID: PMC6974697.
      Citations: 3     
    101. Harrison R, Zhao H, Sun CC, Fu S, Armbruster SD, Westin SN, Rauh-Hain JA, Lu KH, Giordano SH, Meyer LA. Body mass index and attitudes towards health behaviors among women with endometrial cancer before and after treatment. Int J Gynecol Cancer. 2020 02; 30(2):187-192. PMID: 31843871; PMCID: PMC7307445.
      Citations:    Fields:    Translation:Humans
    102. Myers AP, Konstantinopoulos PA, Barry WT, Luo W, Broaddus RR, Makker V, Drapkin R, Liu J, Doyle A, Horowitz NS, Meric-Bernstam F, Birrer M, Aghajanian C, Coleman RL, Mills GB, Cantley LC, Matulonis UA, Westin SN. Phase II, 2-stage, 2-arm, PIK3CA mutation stratified trial of MK-2206 in recurrent endometrial cancer. Int J Cancer. 2020 07 15; 147(2):413-422. PMID: 31714586; PMCID: PMC7214201.
      Citations: 11     Fields:    Translation:HumansCTClinical Trials
    103. Zibetti Dal Molin G, Westin SN, Msaouel P, Gomes LM, Dickens A, Coleman RL. Discrepancy in calculated and measured glomerular filtration rates in patients treated with PARP inhibitors. Int J Gynecol Cancer. 2020 01; 30(1):89-93. PMID: 31792084.
      Citations: 9     Fields:    Translation:Humans
    104. Lara OD, Krishnan S, Wang Z, Corvigno S, Zhong Y, Lyons Y, Dood R, Hu W, Qi L, Liu J, Coleman RL, Westin SN, Fleming ND, Cristini V, Rao A, Burks J, Sood AK. Tumor core biopsies adequately represent immune microenvironment of high-grade serous carcinoma. Sci Rep. 2019 11 26; 9(1):17589. PMID: 31772388; PMCID: PMC6879510.
      Citations: 5     Fields:    Translation:HumansCells
    105. Gallagher JR, Heap KJ, Carroll S, Travers K, Harrow B, Westin SN. Real-world adverse events with niraparib 200 mg/day maintenance therapy in ovarian cancer: a retrospective study. Future Oncol. 2019 Dec; 15(36):4197-4206. PMID: 31707856.
      Citations: 6     Fields:    Translation:Humans
    106. Soliman PT, Westin SN, Iglesias DA, Fellman BM, Yuan Y, Zhang Q, Yates MS, Broaddus RR, Slomovitz BM, Lu KH, Coleman RL. Everolimus, Letrozole, and Metformin in Women with Advanced or Recurrent Endometrioid Endometrial Cancer: A Multi-Center, Single Arm, Phase II Study. Clin Cancer Res. 2020 02 01; 26(3):581-587. PMID: 31628143; PMCID: PMC7002216.
      Citations: 11     Fields:    Translation:Humans
    107. Zhukovsky DS, Soliman PT, Mathew B, Mills S, Bodurka D, Frumovitz M, Meyer LA, Westin S, Nowitz M, Archie L, Fenton S, Lang K, Williams JL, Boving V, Bruera E. Systematic Approach to Selecting and Preparing a Medical Power of Attorney in the Gynecologic Oncology Center. J Oncol Pract. 2019 12; 15(12):e1092-e1097. PMID: 31613720; PMCID: PMC7846063.
      Citations:    Fields:    Translation:Humans
    108. Westin SN, Sill MW, Coleman RL, Waggoner S, Moore KN, Mathews CA, Martin LP, Modesitt SC, Lee S, Ju Z, Mills GB, Schilder RJ, Fracasso PM, Birrer MJ, Aghajanian C. Safety lead-in of the MEK inhibitor trametinib in combination with GSK2141795, an AKT inhibitor, in patients with recurrent endometrial cancer: An NRG Oncology/GOG study. Gynecol Oncol. 2019 12; 155(3):420-428. PMID: 31623857; PMCID: PMC6922584.
      Citations: 13     Fields:    Translation:HumansCTClinical Trials
    109. Ramondetta LM, Hu W, Thaker PH, Urbauer DL, Chisholm GB, Westin SN, Sun Y, Ramirez PT, Fleming N, Sahai SK, Nick AM, Arevalo JMG, Dizon T, Coleman RL, Cole SW, Sood AK. Prospective pilot trial with combination of propranolol with chemotherapy in patients with epithelial ovarian cancer and evaluation on circulating immune cell gene expression. Gynecol Oncol. 2019 09; 154(3):524-530. PMID: 31353053; PMCID: PMC6867685.
      Citations: 10     Fields:    Translation:HumansCellsCTClinical Trials
    110. Kurnit KC, Lu KH, Westin SN. Rapidly Changing Landscape of Fallopian Tube Carcinoma. J Oncol Pract. 2019 07; 15(7):383-384. PMID: 31283416; PMCID: PMC6881185.
      Citations:    Fields:    Translation:Humans
    111. Stewart KI, Chasen B, Erwin W, Fleming N, Westin SN, Dioun S, Frumovitz M, Ramirez PT, Lu KH, Wong F, Aloia TA, Soliman PT. Preoperative PET/CT does not accurately detect extrauterine disease in patients with newly diagnosed high-risk endometrial cancer: A prospective study. Cancer. 2019 10 01; 125(19):3347-3353. PMID: 31225906; PMCID: PMC6744337.
      Citations: 3     Fields:    Translation:Humans
    112. Armbruster SD, Previs R, Soliman PT, Westin SN, Fellman B, Jhingran A, Fleming ND. Clinicopathologic features and treatment in patients with early stage uterine clear cell carcinoma: A 16-year experience. Gynecol Oncol. 2019 08; 154(2):328-332. PMID: 31221496; PMCID: PMC6822694.
      Citations: 2     Fields:    Translation:Humans
    113. Fang Y, McGrail DJ, Sun C, Labrie M, Chen X, Zhang D, Ju Z, Vellano CP, Lu Y, Li Y, Jeong KJ, Ding Z, Liang J, Wang SW, Dai H, Lee S, Sahni N, Mercado-Uribe I, Kim TB, Chen K, Lin SY, Peng G, Westin SN, Liu J, O'Connor MJ, Yap TA, Mills GB. Sequential Therapy with PARP and WEE1 Inhibitors Minimizes Toxicity while Maintaining Efficacy. Cancer Cell. 2019 06 10; 35(6):851-867.e7. PMID: 31185210; PMCID: PMC6642675.
      Citations: 60     Fields:    Translation:HumansAnimalsCells
    114. Labrie M, Kim TB, Ju Z, Lee S, Zhao W, Fang Y, Lu Y, Chen K, Ramirez P, Frumovitz M, Meyer L, Fleming ND, Sood AK, Coleman RL, Mills GB, Westin SN. Adaptive responses in a PARP inhibitor window of opportunity trial illustrate limited functional interlesional heterogeneity and potential combination therapy options. Oncotarget. 2019 May 28; 10(37):3533-3546. PMID: 31191824; PMCID: PMC6544405.
      Citations: 10     Fields:    
    115. Harrison RF, He W, Fu S, Zhao H, Sun CC, Suidan RS, Woodard TL, Rauh-Hain JA, Westin SN, Giordano SH, Meyer LA. National patterns of care and fertility outcomes for reproductive-aged women with endometrial cancer or atypical hyperplasia. Am J Obstet Gynecol. 2019 11; 221(5):474.e1-474.e11. PMID: 31128110; PMCID: PMC7069241.
      Citations: 9     Fields:    Translation:Humans
    116. Hinchcliff E, Westin SN, Dal Molin G, LaFargue CJ, Coleman RL. Poly-ADP-ribose polymerase inhibitor use in ovarian cancer: expanding indications and novel combination strategies. Int J Gynecol Cancer. 2019 May 22. PMID: 31118216; PMCID: PMC8263126.
      Citations: 1     Fields:    
    117. Chapman BV, Swanick CW, Ning MS, Allen PK, Soliman PT, Westin SN, Pardeshi V, Broaddus RR, Lu KH, Jhingran A, Eifel PJ, Klopp AH. Adjuvant combined-modality therapy for stage IIIC endometrioid and non-endometrioid endometrial cancer. Gynecol Oncol. 2019 07; 154(1):22-28. PMID: 31109659; PMCID: PMC7523189.
      Citations: 7     Fields:    Translation:Humans
    118. Gil KM, Pugh SL, Klopp AH, Yeung AR, Wenzel L, Westin SN, Gaffney DK, Small W, Thompson S, Doncals DE, Cantuaria GHC, Yaremko BP, Chang A, Kundapur V, Mohan DS, Haas ML, Kim YB, Ferguson CL, Deshmukh S, Kachnic LA, Bruner DW. Expanded validation of the EPIC bowel and urinary domains for use in women with gynecologic cancer undergoing postoperative radiotherapy. Gynecol Oncol. 2019 07; 154(1):183-188. PMID: 31104905; PMCID: PMC6918674.
      Citations: 5     Fields:    Translation:HumansPHPublic Health
    119. Vreeland TJ, Beaudry Simoneau E, Dewhurst WL, Newhook TE, Westin SN, Mehran RJ, Chun YS, Aloia TA, Vauthey JN, Tzeng CD. Intraoperative Air Leak Test to Prevent Bile Leak After Right Posterior Sectionectomy with En Bloc Diaphragm Resection for Metastatic Teratoma. Ann Surg Oncol. 2019 Aug; 26(8):2579. PMID: 31065963.
      Citations:    Fields:    Translation:Humans
    120. Buechel M, Herzog TJ, Westin SN, Coleman RL, Monk BJ, Moore KN, Buechel M, Herzog TJ, Westin SN, Coleman RL, Monk BJ, Moore KN. Treatment of patients with recurrent epithelial ovarian cancer for whom platinum is still an option. Ann Oncol. 2019 05 01; 30(5):721-732. PMID: 30887020; PMCID: PMC8887593.
      Citations:    
    121. Kurnit KC, Westin SN, Coleman RL. Microsatellite instability in endometrial cancer: New purpose for an old test. Cancer. 2019 07 01; 125(13):2154-2163. PMID: 30913308; PMCID: PMC6763363.
      Citations: 3     Fields:    Translation:Humans
    122. Konstantinopoulos PA, Barry WT, Birrer M, Westin SN, Cadoo KA, Shapiro GI, Mayer EL, O'Cearbhaill RE, Coleman RL, Kochupurakkal B, Whalen C, Curtis J, Farooq S, Luo W, Eismann J, Buss MK, Aghajanian C, Mills GB, Palakurthi S, Kirschmeier P, Liu J, Cantley LC, Kaufmann SH, Swisher EM, D'Andrea AD, Winer E, Wulf GM, Matulonis UA. Olaparib and a-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial. Lancet Oncol. 2019 04; 20(4):570-580. PMID: 30880072; PMCID: PMC7025391.
      Citations: 69     Fields:    Translation:HumansCTClinical Trials
    123. Pal SK, Miller MJ, Agarwal N, Chang SM, Chavez-MacGregor M, Cohen E, Cole S, Dale W, Magid Diefenbach CS, Disis ML, Dreicer R, Graham DL, Henry NL, Jones J, Keedy V, Klepin HD, Markham MJ, Mittendorf EA, Rodriguez-Galindo C, Sabel MS, Schilsky RL, Sznol M, Tap WD, Westin SN, Johnson BE. Clinical Cancer Advances 2019: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. J Clin Oncol. 2019 04 01; 37(10):834-849. PMID: 30702028.
      Citations: 31     Fields:    Translation:Humans
    124. Labrie M, Fang Y, Kendsersky ND, Li J, Liang H, Westin SN, Mitri Z, Mills GB. Using Reverse Phase Protein Array (RPPA) to Identify and Target Adaptive Resistance. Adv Exp Med Biol. 2019; 1188:251-266. PMID: 31820393; PMCID: PMC7382818.
      Citations: 7     Fields:    Translation:Humans
    125. Bruinooge SS, Pickard TA, Vogel W, Hanley A, Schenkel C, Garrett-Mayer E, Tetzlaff E, Rosenzweig M, Hylton H, Westin SN, Lynch C, Kosty MP, Williams SF, Smith N. Understanding the role of advanced practice providers in oncology in the United States. JAAPA. 2018 Dec; 31(12):1-12. PMID: 30489397.
      Citations:    Fields:    Translation:Humans
    126. Kurnit KC, Coleman RL, Westin SN. Using PARP Inhibitors in the Treatment of Patients With Ovarian Cancer. Curr Treat Options Oncol. 2018 11 15; 19(12):1. PMID: 30535808; PMCID: PMC8240125.
      Citations: 14     Fields:    Translation:Humans
    127. Kurnit KC, Previs RA, Soliman PT, Westin SN, Klopp AH, Fellman BM, Lu KH, Ramondetta LM, Fleming ND. Prognostic factors impacting survival in early stage uterine carcinosarcoma. Gynecol Oncol. 2019 01; 152(1):31-37. PMID: 30414738; PMCID: PMC6321768.
      Citations: 7     Fields:    Translation:Humans
    128. Bruinooge S, Pickard TA, Vogel W, Hanley A, Schenkel C, Garrett-Mayer E, Tetzlaff E, Rosenzweig M, Hylton H, Westin SN, Smith N, Lynch C, Kosty MP, Williams SF. Understanding the Role of Advanced Practice Providers in Oncology in the United States. Oncol Nurs Forum. 2018 11 01; 45(6):786-800. PMID: 30339144.
      Citations: 1     Fields:    Translation:Humans
    129. Hansen JM, Sood AK, Coleman RL, Westin SN, Soliman PT, Ramirez PT, Fellman BM, Schmeler KM, Fleming ND. Concordance of a laparoscopic scoring algorithm with primary surgery findings in advanced stage ovarian cancer. Gynecol Oncol. 2018 12; 151(3):428-432. PMID: 30366647; PMCID: PMC6281799.
      Citations: 4     Fields:    Translation:Humans
    130. Dood RL, Fleming ND, Coleman RL, Westin SN, Lara OD, LaFargue CJ, Liu J, Sood AK. When Ovarian Cancer Is Not: Characterizing Nonovarian Cancer Pathology in a Laparoscopy-Based Triage System. Int J Gynecol Cancer. 2018 10; 28(8):1485-1490. PMID: 30036226; PMCID: PMC6355335.
      Citations: 2     Fields:    Translation:Humans
    131. Jazaeri A, Coleman RL, Sood AK, Frumovitz MM, Soliman PT, Shafer A, Cutrera JJ, Klinger M, Sharafi SE, Johnson CAL, Villanueva VF, Hinchcliff EM, Dickens A, Cain KE, Anderson JE, Lu KH, Westin SN. A practical guide for the safe implementation of early phase drug development and immunotherapy program in gynecologic oncology practice. Gynecol Oncol. 2018 11; 151(2):374-380. PMID: 30213435; PMCID: PMC6235625.
      Citations:    Fields:    Translation:Humans
    132. Fleming ND, Nick AM, Coleman RL, Westin SN, Ramirez PT, Soliman PT, Fellman B, Meyer LA, Schmeler KM, Lu KH, Sood AK. Laparoscopic Surgical Algorithm to Triage the Timing of Tumor Reductive Surgery in Advanced Ovarian Cancer. Obstet Gynecol. 2018 09; 132(3):545-554. PMID: 30095787; PMCID: PMC6105510.
      Citations: 17     Fields:    Translation:Humans
    133. Bruinooge SS, Pickard TA, Vogel W, Hanley A, Schenkel C, Garrett-Mayer E, Tetzlaff E, Rosenzweig M, Hylton H, Westin SN, Lynch C, Kosty MP, Williams SF, Smith N. Understanding the Role of Advanced Practice Providers in Oncology in the United States. J Adv Pract Oncol. 2018 Sep-Oct; 9(6):585-598. PMID: 31186981; PMCID: PMC6505663.
      Citations: 6     
    134. Bruinooge SS, Pickard TA, Vogel W, Hanley A, Schenkel C, Garrett-Mayer E, Tetzlaff E, Rosenzweig M, Hylton H, Westin SN, Lynch C, Kosty MP, Williams SF, Smith N. Understanding the Role of Advanced Practice Providers in Oncology in the United States. J Oncol Pract. 2018 09; 14(9):e518-e532. PMID: 30133346.
      Citations: 14     Fields:    Translation:Humans
    135. Nishio S, Matsuo K, Yonemoto K, Shimokawa M, Hosaka M, Kodama M, Miyake TM, Ushijima K, Kamura T, Westin SN, Soliman PT, Coleman RL. Race and nodal disease status are prognostic factors in patients with stage IVB cervical cancer. Oncotarget. 2018 Aug 17; 9(64):32321-32330. PMID: 30190789; PMCID: PMC6122357.
      Citations: 3     Fields:    
    136. Dal Molin GZ, Westin SN, Coleman RL. Rucaparib in ovarian cancer: extending the use of PARP inhibitors in the recurrent disease. Future Oncol. 2018 Dec; 14(30):3101-3110. PMID: 30105925; PMCID: PMC6331693.
      Citations: 4     Fields:    Translation:Humans
    137. Klopp AH, Yeung AR, Deshmukh S, Gil KM, Wenzel L, Westin SN, Gifford K, Gaffney DK, Small W, Thompson S, Doncals DE, Cantuaria GHC, Yaremko BP, Chang A, Kundapur V, Mohan DS, Haas ML, Kim YB, Ferguson CL, Pugh SL, Kachnic LA, Bruner DW. Patient-Reported Toxicity During Pelvic Intensity-Modulated Radiation Therapy: NRG Oncology-RTOG 1203. J Clin Oncol. 2018 08 20; 36(24):2538-2544. PMID: 29989857; PMCID: PMC6097832.
      Citations: 59     Fields:    Translation:HumansPHPublic HealthCTClinical Trials
    138. Suidan RS, Sun CC, Cantor SB, Mariani A, Soliman PT, Westin SN, Lu KH, Giordano SH, Meyer LA. Three Lymphadenectomy Strategies in Low-Risk Endometrial Carcinoma: A Cost-Effectiveness Analysis. Obstet Gynecol. 2018 07; 132(1):52-58. PMID: 29889752; PMCID: PMC6294436.
      Citations: 4     Fields:    Translation:Humans
    139. Colombo I, Kurnit KC, Westin SN, Oza AM. Moving From Mutation to Actionability. Am Soc Clin Oncol Educ Book. 2018 May 23; 38:495-503. PMID: 30231353.
      Citations: 1     Fields:    Translation:HumansCells
    140. Jalloul RJ, Nick AM, Munsell MF, Westin SN, Ramirez PT, Frumovitz M, Soliman PT. The influence of surgeon volume on outcomes after pelvic exenteration for a gynecologic cancer. J Gynecol Oncol. 2018 Sep; 29(5):e68. PMID: 30022632; PMCID: PMC6078889.
      Citations: 4     Fields:    Translation:Humans
    141. Euscher E, Sui D, Soliman P, Westin S, Ramalingam P, Bassett R, Malpica A. Ultrastaging of Sentinel Lymph Nodes in Endometrial Carcinoma According to Use of 2 Different Methods. Int J Gynecol Pathol. 2018 May; 37(3):242-251. PMID: 28700425.
      Citations: 8     Fields:    Translation:Humans
    142. Sen S, Kato S, Agarwal R, Piha-Paul S, Hess K, Karp D, Janku F, Fu S, Naing A, Pant S, Falchook G, Tang C, Wu X, Ye Y, Tsimberidou A, Subbiah V, Kurzrock R, Byers L, Westin S, Lim J, Bean S, Bass A, Nguyen L, Meric-Bernstam F, Hong D. Phase I study of nab-paclitaxel, gemcitabine, and bevacizumab in patients with advanced cancers. Br J Cancer. 2018 05; 118(11):1419-1424. PMID: 29695765; PMCID: PMC5988803.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    143. Armbruster SD, Sun CC, Westin SN, Bodurka DC, Ramondetta L, Meyer LA, Soliman PT. Prospective assessment of patient-reported outcomes in gynecologic cancer patients before and after pelvic exenteration. Gynecol Oncol. 2018 06; 149(3):484-490. PMID: 29622276; PMCID: PMC5986607.
      Citations: 2     Fields:    Translation:Humans
    144. Heymach J, Krilov L, Alberg A, Baxter N, Chang SM, Corcoran RB, Dale W, DeMichele A, Magid Diefenbach CS, Dreicer R, Epstein AS, Gillison ML, Graham DL, Jones J, Ko AH, Lopez AM, Maki RG, Rodriguez-Galindo C, Schilsky RL, Sznol M, Westin SN, Burstein H. Clinical Cancer Advances 2018: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. J Clin Oncol. 2018 04 01; 36(10):1020-1044. PMID: 29380678.
      Citations: 42     Fields:    Translation:Humans
    145. Pal N, Broaddus RR, Urbauer DL, Balakrishnan N, Milbourne A, Schmeler KM, Meyer LA, Soliman PT, Lu KH, Ramirez PT, Ramondetta L, Bodurka DC, Westin SN. Treatment of Low-Risk Endometrial Cancer and Complex Atypical Hyperplasia With the Levonorgestrel-Releasing Intrauterine Device. Obstet Gynecol. 2018 01; 131(1):109-116. PMID: 29215513; PMCID: PMC5739955.
      Citations: 45     Fields:    Translation:Humans
    146. Mauland KK, Ju Z, Berg A, Kalland KH, Westin SN, Krakstad C, Trovik J, Mills GB, Hoivik EA, Johanna Werner HM, Tangen IL, ?yan AM, Bj?rge L. Proteomic profiling of endometrioid endometrial cancer reveals differential expression of hormone receptors and MAPK signaling proteins in obese versus non-obese patients. Oncotarget. 2017 Dec 05; 8(63):106989-107001. PMID: 29291005; PMCID: PMC5739790.
      Citations: 3     Fields:    
    147. Banerji U, Dean EJ, Batist G, Bedard PL, Westin SN, Kabos P, Garrett MD, Tall M, Ambrose H, Barrett JC, Carr TH, Cheung SYA, Corcoran C, Cullberg M, Davies BR, de Bruin EC, Elvin P, Foxley A, Lawrence P, Lindemann JPO, Maudsley R, Pass M, Rowlands V, Rugman P, Schiavon G, Yates J, Schellens JHM, P?rez-Fidalgo JA, You B. A Phase I Open-Label Study to Identify a Dosing Regimen of the Pan-AKT Inhibitor AZD5363 for Evaluation in Solid Tumors and in PIK3CA-Mutated Breast and Gynecologic Cancers. Clin Cancer Res. 2018 05 01; 24(9):2050-2059. PMID: 29066505.
      Citations: 46     Fields:    Translation:HumansCTClinical Trials
    148. Newtson AM, Pakish JB, Nick AM, Westin SN. Dual progestin therapy for fertility-sparing treatment of grade 2 endometrial adenocarcinoma. Gynecol Oncol Rep. 2017 Aug; 21:117-118. PMID: 28831417; PMCID: PMC5554929.
      Citations:    
    149. Corzo C, Barrientos Santillan N, Westin SN, Ramirez PT. Updates on Conservative Management of Endometrial Cancer. J Minim Invasive Gynecol. 2018 02; 25(2):308-313. PMID: 28782618.
      Citations: 34     Fields:    Translation:Humans
    150. Fleming ND, Coleman RL, Tung C, Westin SN, Hu W, Sun Y, Bhosale P, Munsell MF, Sood AK. Phase II trial of bevacizumab with dose-dense paclitaxel as first-line treatment in patients with advanced ovarian cancer. Gynecol Oncol. 2017 10; 147(1):41-46. PMID: 28774461; PMCID: PMC5605462.
      Citations: 9     Fields:    Translation:HumansCTClinical Trials
    151. Khafagy AM, Prescott LS, Malpica A, Westin SN. Unusual indolent behavior of leiomyosarcoma of the vagina: Is observation a viable option? Gynecol Oncol Rep. 2017 Aug; 21:28-30. PMID: 28649595; PMCID: PMC5472150.
      Citations:    
    152. Bednar EM, Oakley HD, Sun CC, Burke CC, Munsell MF, Westin SN, Lu KH. A universal genetic testing initiative for patients with high-grade, non-mucinous epithelial ovarian cancer and the implications for cancer treatment. Gynecol Oncol. 2017 08; 146(2):399-404. PMID: 28610746; PMCID: PMC5881383.
      Citations: 21     Fields:    Translation:HumansPHPublic Health
    153. Sun C, Fang Y, Yin J, Chen J, Ju Z, Zhang D, Chen X, Vellano CP, Jeong KJ, Ng PK, Eterovic AKB, Bhola NH, Lu Y, Westin SN, Grandis JR, Lin SY, Scott KL, Peng G, Brugge J, Mills GB. Rational combination therapy with PARP and MEK inhibitors capitalizes on therapeutic liabilities in RAS mutant cancers. Sci Transl Med. 2017 05 31; 9(392). PMID: 28566428; PMCID: PMC5919217.
      Citations: 80     Fields:    Translation:AnimalsCells
    154. Soliman PT, Westin SN, Dioun S, Sun CC, Euscher E, Munsell MF, Fleming ND, Levenback C, Frumovitz M, Ramirez PT, Lu KH. A prospective validation study of sentinel lymph node mapping for high-risk endometrial cancer. Gynecol Oncol. 2017 08; 146(2):234-239. PMID: 28528918; PMCID: PMC5860676.
      Citations: 36     Fields:    Translation:Humans
    155. Hyman DM, Smyth LM, Donoghue MTA, Westin SN, Bedard PL, Dean EJ, Bando H, El-Khoueiry AB, P?rez-Fidalgo JA, Mita A, Schellens JHM, Chang MT, Reichel JB, Bouvier N, Selcuklu SD, Soumerai TE, Torrisi J, Erinjeri JP, Ambrose H, Barrett JC, Dougherty B, Foxley A, Lindemann JPO, McEwen R, Pass M, Schiavon G, Berger MF, Chandarlapaty S, Solit DB, Banerji U, Baselga J, Taylor BS. AKT Inhibition in Solid Tumors With AKT1 Mutations. J Clin Oncol. 2017 Jul 10; 35(20):2251-2259. PMID: 28489509; PMCID: PMC5501365.
      Citations: 118     Fields:    Translation:HumansCells
    156. Holman LL, Pal N, Iglesias DA, Soliman PT, Balakrishnan N, Klopp A, Broaddus RR, Fleming ND, Munsell MF, Lu KH, Westin SN. Factors prognostic of survival in advanced-stage uterine serous carcinoma. Gynecol Oncol. 2017 07; 146(1):27-33. PMID: 28465008; PMCID: PMC5539404.
      Citations: 12     Fields:    Translation:Humans
    157. Matulonis UA, Wulf GM, Barry WT, Birrer M, Westin SN, Farooq S, Bell-McGuinn KM, Obermayer E, Whalen C, Spagnoletti T, Luo W, Liu H, Hok RC, Aghajanian C, Solit DB, Mills GB, Taylor BS, Won H, Berger MF, Palakurthi S, Liu J, Cantley LC, Winer E. Phase I dose escalation study of the PI3kinase pathway inhibitor BKM120 and the oral poly (ADP ribose) polymerase (PARP) inhibitor olaparib for the treatment of high-grade serous ovarian and breast cancer. Ann Oncol. 2017 03 01; 28(3):512-518. PMID: 27993796; PMCID: PMC5834157.
      Citations: 74     Fields:    Translation:HumansCTClinical Trials
    158. Westin SN, Coleman RL. Individualized Medicine in Ovarian Cancer: Are We There Yet? Gynecol Oncol. 2017 02; 144(2):229-231. PMID: 28089051; PMCID: PMC5881923.
      Citations:    Fields:    Translation:Humans
    159. Suidan RS, He W, Sun CC, Zhao H, Fleming ND, Ramirez PT, Soliman PT, Westin SN, Lu KH, Giordano SH, Meyer LA. Impact of body mass index and operative approach on surgical morbidity and costs in women with endometrial carcinoma and hyperplasia. Gynecol Oncol. 2017 04; 145(1):55-60. PMID: 28131529; PMCID: PMC5557389.
      Citations: 9     Fields:    Translation:Humans
    160. Previs RA, Sood AK, Mills GB, Westin SN. The rise of genomic profiling in ovarian cancer. Expert Rev Mol Diagn. 2016 12; 16(12):1337-1351. PMID: 27828713; PMCID: PMC5659206.
      Citations: 11     Fields:    Translation:HumansCells
    161. Soliman PT, Zhang Q, Broaddus RR, Westin SN, Iglesias D, Munsell MF, Schmandt R, Yates M, Ramondetta L, Lu KH. Prospective evaluation of the molecular effects of metformin on the endometrium in women with newly diagnosed endometrial cancer: A window of opportunity study. Gynecol Oncol. 2016 Dec; 143(3):466-471. PMID: 27745917; PMCID: PMC5116402.
      Citations: 23     Fields:    Translation:Humans
    162. Fleming ND, Ramirez PT, Soliman PT, Schmeler KM, Chisholm GB, Nick AM, Westin SN, Frumovitz M. Quality of life after radical trachelectomy for early-stage cervical cancer: A 5-year prospective evaluation. Gynecol Oncol. 2016 Dec; 143(3):596-603. PMID: 27742473; PMCID: PMC5439265.
      Citations: 7     Fields:    Translation:Humans
    163. Hou MM, Wang Z, Janku F, Piha-Paul S, Naing A, Hong D, Westin S, Coleman RL, Sood AK, Tsimberidou AM, Subbiah V, Wheler J, Zinner R, Lu K, Meric-Bernstam F, Fu S. Continuous anti-angiogenic therapy after tumor progression in patients with recurrent high-grade epithelial ovarian cancer: phase I trial experience. Oncotarget. 2016 Jun 07; 7(23):35132-43. PMID: 27147567; PMCID: PMC5085215.
      Citations: 6     Fields:    Translation:Humans
    164. Meyer L, Suidan R, Sun C, Westin S, Coleman RL, Mills GB. The management of malignant ascites and impact on quality of life outcomes in women with ovarian cancer. Expert Rev Qual Life Cancer Care. 2016; 1(3):231-238. PMID: 30906877; PMCID: PMC6425954.
      Citations: 6     
    165. Goldstein J, Pandey P, Fleming N, Westin S, Piha-Paul S. A non-pregnant woman with elevated beta-HCG: A case of para-neoplastic syndrome in ovarian cancer. Gynecol Oncol Rep. 2016 Aug; 17:49-52. PMID: 27355002; PMCID: PMC4910296.
      Citations: 6     
    166. Liu J, Westin SN. Rational selection of biomarker driven therapies for gynecologic cancers: The more we know, the more we know we don't know. Gynecol Oncol. 2016 Apr; 141(1):65-71. PMID: 27016231; PMCID: PMC4808566.
      Citations: 4     Fields:    Translation:Humans
    167. Westin SN, Randall L. The European Society of Gynecologic Oncology (ESGO) 19th biannual meeting: Overview and summary of selected topics. Gynecol Oncol. 2016 Mar; 140(3):377-80. PMID: 26807487; PMCID: PMC7478139.
      Citations:    Fields:    Translation:Humans
    168. Westin SN, Soliman PT, Escobar PF, Frumovitz M, Ramirez PT, Darin MC, G?mez-Hidalgo NR. Role of Indocyanine Green in Sentinel Node Mapping in Gynecologic Cancer: Is Fluorescence Imaging the New Standard? J Minim Invasive Gynecol. 2016 Feb 01; 23(2):186-93. PMID: 26518716.
      Citations: 8     Fields:    Translation:Humans
    169. Holman LL, Ren Y, Westin SN. Status epilepticus associated with platinum chemotherapy in a patient with cervical cancer: a case report. BMC Cancer. 2015 Oct 17; 15:728. PMID: 26474752; PMCID: PMC4609077.
      Citations: 2     Fields:    Translation:Humans
    170. Soliman PT, Westin SN, dos Reis R, Munsell M, Klopp AH, Frumovitz M, Nick AM, Schmeler K, Ramirez PT, Fleming ND. Impact of Lymph Node Ratio and Adjuvant Therapy in Node-Positive Endometrioid Endometrial Cancer. Int J Gynecol Cancer. 2015 Oct; 25(8):1437-44. PMID: 26332387; PMCID: PMC4581897.
      Citations: 8     Fields:    Translation:Humans
    171. Burzawa JK, Tsunoda AT, Hosaka M, Frumovitz M, Westin SN, Munsell MF, Ramirez PT, dos Reis R. Lymphovascular Space Invasion Portends Poor Prognosis in Low-Risk Endometrial Cancer. Int J Gynecol Cancer. 2015 Sep; 25(7):1292-9. PMID: 26067863; PMCID: PMC4549160.
      Citations: 19     Fields:    Translation:Humans
    172. Westin SN, Sun CC, Tung CS, Lacour RA, Meyer LA, Urbauer DL, Frumovitz MM, Lu KH, Bodurka DC. Survivors of gynecologic malignancies: impact of treatment on health and well-being. J Cancer Surviv. 2016 Apr; 10(2):261-70. PMID: 26245979; PMCID: PMC4744585.
      Citations: 16     Fields:    Translation:Humans
    173. Yang JY, Werner HM, Li J, Westin SN, Lu Y, Halle MK, Trovik J, Salvesen HB, Mills GB, Liang H. Integrative Protein-Based Prognostic Model for Early-Stage Endometrioid Endometrial Cancer. Clin Cancer Res. 2016 Jan 15; 22(2):513-23. PMID: 26224872; PMCID: PMC4715969.
      Citations: 12     Fields:    Translation:Humans
    174. Arms RG, Sun CC, Burzawa JK, Fleming ND, Nick AM, Rallapalli V, Westin SN, Meyer LA, Ramirez PT, Soliman PT. Improvement in quality of life after robotic surgery results in patient satisfaction. Gynecol Oncol. 2015 Sep; 138(3):727-30. PMID: 26197762; PMCID: PMC4816594.
      Citations: 6     Fields:    Translation:Humans
    175. Ho JC, Allen PK, Jhingran A, Westin SN, Lu KH, Eifel PJ, Klopp AH. Management of nodal recurrences of endometrial cancer with IMRT. Gynecol Oncol. 2015 Oct; 139(1):40-6. PMID: 26193429; PMCID: PMC4915591.
      Citations: 9     Fields:    Translation:Humans
    176. Westin SN, Ju Z, Broaddus RR, Krakstad C, Li J, Pal N, Lu KH, Coleman RL, Hennessy BT, Klempner SJ, Werner HM, Salvesen HB, Cantley LC, Mills GB, Myers AP. PTEN loss is a context-dependent outcome determinant in obese and non-obese endometrioid endometrial cancer patients. Mol Oncol. 2015 Oct; 9(8):1694-703. PMID: 26045339; PMCID: PMC4584169.
      Citations: 21     Fields:    Translation:HumansCells
    177. Fleming ND, Frumovitz M, Schmeler KM, dos Reis R, Munsell MF, Eifel PJ, Soliman PT, Nick AM, Westin SN, Ramirez PT. Significance of lymph node ratio in defining risk category in node-positive early stage cervical cancer. Gynecol Oncol. 2015 Jan; 136(1):48-53. PMID: 25451695; PMCID: PMC4430191.
      Citations: 40     Fields:    Translation:Humans
    178. Carroll A, Ramirez PT, Westin SN, Soliman PT, Munsell MF, Nick AM, Schmeler KM, Klopp AH, Fleming ND. Uterine adenosarcoma: an analysis on management, outcomes, and risk factors for recurrence. Gynecol Oncol. 2014 Dec; 135(3):455-61. PMID: 25449308; PMCID: PMC4430193.
      Citations: 29     Fields:    Translation:Humans
    179. Ulm MA, Fleming ND, Rallapali V, Munsell MF, Ramirez PT, Westin SN, Nick AM, Schmeler KM, Soliman PT. Position-related injury is uncommon in robotic gynecologic surgery. Gynecol Oncol. 2014 Dec; 135(3):534-8. PMID: 25449565; PMCID: PMC4268144.
      Citations: 4     Fields:    Translation:Humans
    180. Costales AB, Schmeler KM, Broaddus R, Soliman PT, Westin SN, Ramirez PT, Frumovitz M. Clinically significant endometrial cancer risk following a diagnosis of complex atypical hyperplasia. Gynecol Oncol. 2014 Dec; 135(3):451-4. PMID: 25316176; PMCID: PMC4268403.
      Citations: 6     Fields:    Translation:Humans
    181. Brana I, Berger R, Golan T, Haluska P, Edenfield J, Fiorica J, Stephenson J, Martin LP, Westin S, Hanjani P, Jones MB, Almhanna K, Wenham RM, Sullivan DM, Dalton WS, Gunchenko A, Cheng JD, Siu LL, Gray JE. A parallel-arm phase I trial of the humanised anti-IGF-1R antibody dalotuzumab in combination with the AKT inhibitor MK-2206, the mTOR inhibitor ridaforolimus, or the NOTCH inhibitor MK-0752, in patients with advanced solid tumours. Br J Cancer. 2014 Nov 11; 111(10):1932-44. PMID: 25290091; PMCID: PMC4229637.
      Citations: 29     Fields:    Translation:HumansCTClinical Trials
    182. Westin SN, Rallapalli V, Fellman B, Urbauer DL, Pal N, Frumovitz MM, Ramondetta LM, Bodurka DC, Ramirez PT, Soliman PT. Overall survival after pelvic exenteration for gynecologic malignancy. Gynecol Oncol. 2014 Sep; 134(3):546-51. PMID: 25014540; PMCID: PMC4160382.
      Citations: 23     Fields:    Translation:Humans
    183. Rauch GM, Kaur H, Choi H, Ernst RD, Klopp AH, Boonsirikamchai P, Westin SN, Marcal LP. Optimization of MR imaging for pretreatment evaluation of patients with endometrial and cervical cancer. Radiographics. 2014 Jul-Aug; 34(4):1082-98. PMID: 25019443; PMCID: PMC4307629.
      Citations: 19     Fields:    Translation:Humans
    184. Slaughter KN, Frumovitz M, Schmeler KM, Nick AM, Fleming ND, Munsell MF, Westin SN, Soliman PT, Ramirez PT, dos Reis R. Minimally invasive surgery for endometrial cancer: does operative start time impact surgical and oncologic outcomes? Gynecol Oncol. 2014 Aug; 134(2):248-52. PMID: 24945591; PMCID: PMC4286393.
      Citations: 5     Fields:    Translation:Humans
    185. Jones N, Fleming ND, Nick AM, Munsell MF, Rallapalli V, Westin SN, Meyer LA, Schmeler KM, Ramirez PT, Soliman PT. Conversion from robotic surgery to laparotomy: a case-control study evaluating risk factors for conversion. Gynecol Oncol. 2014 Aug; 134(2):238-42. PMID: 24937481; PMCID: PMC4125462.
      Citations: 7     Fields:    Translation:Humans
    186. Slomovitz BM, Djordjevic B, Westin SN, Iglesias DA, Munsell MF, Jiang Y, Schmandt R, Broaddus RR, Coleman RL, Galbincea JM, Lu KH, Meyer LA. The search continues: looking for predictive biomarkers for response to mammalian target of rapamycin inhibition in endometrial cancer. Int J Gynecol Cancer. 2014 May; 24(4):713-7. PMID: 24651628; PMCID: PMC4039301.
      Citations: 12     Fields:    Translation:HumansCTClinical Trials
    187. Jardim DL, Wheler JJ, Hess K, Tsimberidou AM, Zinner R, Janku F, Subbiah V, Naing A, Piha-Paul SA, Westin SN, Roy-Chowdhuri S, Meric-Bernstam F, Hong DS. FBXW7 mutations in patients with advanced cancers: clinical and molecular characteristics and outcomes with mTOR inhibitors. PLoS One. 2014; 9(2):e89388. PMID: 24586741; PMCID: PMC3929689.
      Citations: 30     Fields:    Translation:Humans
    188. Subbiah V, Westin SN, Wang K, Araujo D, Wang WL, Miller VA, Ross JS, Stephens PJ, Palmer GA, Ali SM. Targeted therapy by combined inhibition of the RAF and mTOR kinases in malignant spindle cell neoplasm harboring the KIAA1549-BRAF fusion protein. J Hematol Oncol. 2014 Jan 14; 7:8. PMID: 24422672; PMCID: PMC3896681.
      Citations: 31     Fields:    Translation:HumansCTClinical Trials
    189. Bruegl AS, Djordjevic B, Urbauer DL, Westin SN, Soliman PT, Lu KH, Luthra R, Broaddus RR. Utility of MLH1 methylation analysis in the clinical evaluation of Lynch Syndrome in women with endometrial cancer. Curr Pharm Des. 2014; 20(11):1655-63. PMID: 23888949; PMCID: PMC3895501.
      Citations: 11     Fields:    Translation:HumansCells
    190. Pakish J, Soliman PT, Frumovitz M, Westin SN, Schmeler KM, Reis RD, Munsell MF, Ramirez PT. A comparison of extraperitoneal versus transperitoneal laparoscopic or robotic para-aortic lymphadenectomy for staging of endometrial carcinoma. Gynecol Oncol. 2014 Feb; 132(2):366-71. PMID: 24361579; PMCID: PMC4116735.
      Citations: 9     Fields:    Translation:Humans
    191. Tang C, Jardim DL, Falchook GS, Hess K, Fu S, Wheler JJ, Zinner RG, Naing A, Tsimberidou AM, De Melo Galgiato D, Westin SN, Meric-Bernstam F, Kurzrock R, Hong DS. MET nucleotide variations and amplification in advanced ovarian cancer: characteristics and outcomes with c-Met inhibitors. Oncoscience. 2014; 1(1):5-13. PMID: 25593979; PMCID: PMC4295762.
      Citations: 19     
    192. Huang M, Iglesias DA, Westin SN, Fellman B, Urbauer D, Schmeler KM, Frumovitz M, Ramirez PT, Soliman PT. Pelvic exenteration: impact of age on surgical and oncologic outcomes. Gynecol Oncol. 2014 Jan; 132(1):114-8. PMID: 24262877; PMCID: PMC3936604.
      Citations: 6     Fields:    Translation:Humans
    193. Soliman PT, Iglesias D, Munsell MF, Frumovitz M, Westin SN, Nick AM, Schmeler KM, Ramirez PT. Successful incorporation of robotic surgery into gynecologic oncology fellowship training. Gynecol Oncol. 2013 Dec; 131(3):730-3. PMID: 24055616; PMCID: PMC3856555.
      Citations: 3     Fields:    Translation:Humans
    194. Clark LH, Soliman PT, Odetto D, Munsell MF, Schmeler KM, Fleming N, Westin SN, Nick AM, Ramirez PT. Incidence of trocar site herniation following robotic gynecologic surgery. Gynecol Oncol. 2013 Nov; 131(2):400-3. PMID: 23988416; PMCID: PMC4158736.
      Citations: 11     Fields:    Translation:Humans
    195. Klempner SJ, Myers AP, Mills GB, Westin SN. Clinical investigation of receptor and non-receptor tyrosine kinase inhibitors for the treatment of epithelial ovarian cancer. Expert Opin Pharmacother. 2013 Nov; 14(16):2171-82. PMID: 23937415; PMCID: PMC4103698.
      Citations: 5     Fields:    Translation:Humans
    196. Huang M, Djordjevic B, Yates MS, Urbauer D, Sun C, Burzawa J, Daniels M, Westin SN, Broaddus R, Lu K. Molecular pathogenesis of endometrial cancers in patients with Lynch syndrome. Cancer. 2013 Aug 15; 119(16):3027-33. PMID: 23760948; PMCID: PMC4120439.
      Citations: 6     Fields:    Translation:HumansCells
    197. Urh A, Soliman PT, Schmeler KM, Westin S, Frumovitz M, Nick AM, Fellman B, Urbauer DL, Ramirez PT. Postoperative outcomes after continent versus incontinent urinary diversion at the time of pelvic exenteration for gynecologic malignancies. Gynecol Oncol. 2013 Jun; 129(3):580-5. PMID: 23480870; PMCID: PMC3935607.
      Citations: 8     Fields:    Translation:Humans
    198. Westin SN, Mills GB, Myers AP. Repurposing the Pap smear: one step closer to gynecologic cancer screening. Sci Transl Med. 2013 Jan 09; 5(167):167ps1. PMID: 23303602; PMCID: PMC3824959.
      Citations: 1     Fields:    Translation:Humans
    199. Djordjevic B, Westin S, Broaddus RR. Application of Immunohistochemistry and Molecular Diagnostics to Clinically Relevant Problems in Endometrial Cancer Bojana Djordjevic, Shannon Westin, Russell R. Broaddus. Surg Pathol Clin. 2012 Dec 01; 5(4):859-878. PMID: 23687522; PMCID: PMC3653323.
      Citations: 3     Fields:    
    200. Liang H, Cheung LW, Li J, Ju Z, Yu S, Stemke-Hale K, Dogruluk T, Lu Y, Liu X, Gu C, Guo W, Scherer SE, Carter H, Westin SN, Dyer MD, Verhaak RG, Zhang F, Karchin R, Liu CG, Lu KH, Broaddus RR, Scott KL, Hennessy BT, Mills GB. Whole-exome sequencing combined with functional genomics reveals novel candidate driver cancer genes in endometrial cancer. Genome Res. 2012 Nov; 22(11):2120-9. PMID: 23028188; PMCID: PMC3483541.
      Citations: 126     Fields:    Translation:HumansCells
    201. Westin SN, Herzog TJ, Coleman RL. Investigational agents in development for the treatment of ovarian cancer. Invest New Drugs. 2013 Feb; 31(1):213-29. PMID: 22661305; PMCID: PMC4103697.
      Citations: 13     Fields:    Translation:HumansCells
    202. Covert WM, Westin SN, Soliman PT, Langley GD. The role of mucoregulatory agents after continence-preserving urinary diversion surgery. Am J Health Syst Pharm. 2012 Mar 15; 69(6):483-6. PMID: 22382478.
      Citations: 1     Fields:    Translation:Humans
    203. Brown AJ, Westin SN, Broaddus RR, Schmeler K. Progestin intrauterine device in an adolescent with grade 2 endometrial cancer. Obstet Gynecol. 2012 Feb; 119(2 Pt 2):423-426. PMID: 22270425; PMCID: PMC3266511.
      Citations: 12     Fields:    Translation:Humans
    204. Janku F, Wheler JJ, Westin SN, Moulder SL, Naing A, Tsimberidou AM, Fu S, Falchook GS, Hong DS, Garrido-Laguna I, Luthra R, Lee JJ, Lu KH, Kurzrock R. PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations. J Clin Oncol. 2012 Mar 10; 30(8):777-82. PMID: 22271473; PMCID: PMC3295566.
      Citations: 225     Fields:    Translation:Humans
    205. Iglesias DA, Westin SN, Rallapalli V, Huang M, Fellman B, Urbauer D, Frumovitz M, Ramirez PT, Soliman PT. The effect of body mass index on surgical outcomes and survival following pelvic exenteration. Gynecol Oncol. 2012 May; 125(2):336-42. PMID: 22261299; PMCID: PMC3850365.
      Citations: 3     Fields:    Translation:Humans
    206. Westin SN, Broaddus RR. Personalized therapy in endometrial cancer: challenges and opportunities. Cancer Biol Ther. 2012 Jan 01; 13(1):1-13. PMID: 22198566; PMCID: PMC3335980.
      Citations: 26     Fields:    Translation:Humans
    207. Berger JL, Westin SN, Fellman B, Rallapali V, Frumovitz M, Ramirez PT, Sood AK, Soliman PT. Modified vertical rectus abdominis myocutaneous flap vaginal reconstruction: an analysis of surgical outcomes. Gynecol Oncol. 2012 Apr; 125(1):252-5. PMID: 22166844; PMCID: PMC4264595.
      Citations: 5     Fields:    Translation:Humans
    208. Soliman PT, Frumovitz M, Sun CC, Dos Reis R, Schmeler KM, Nick AM, Westin SN, Brown J, Levenback CF, Ramirez PT. Radical hysterectomy: a comparison of surgical approaches after adoption of robotic surgery in gynecologic oncology. Gynecol Oncol. 2011 Nov; 123(2):333-6. PMID: 21872911; PMCID: PMC4264587.
      Citations: 33     Fields:    Translation:Humans
    209. Kincey J, Westin SN, Zhao B, Curtis MG, Ramondetta L. Surgical removal of a gigantic abdominal mass: a multidisciplinary approach. Obstet Gynecol. 2011 Feb; 117(2 Pt 2):508-512. PMID: 21252807.
      Citations: 2     Fields:    Translation:Humans
    210. Lacour RA, Westin SN, Meyer LA, Wingo SN, Schorge JO, Brooks R, Mutch D, Molina A, Sutphen R, Barnes M, Elder J, Teoh D, Powell CB, Choubey V, Blank S, Macdonald HR, Brady MF, Urbauer DL, Bodurka D, Gershenson DM, Lu KH. Improved survival in non-Ashkenazi Jewish ovarian cancer patients with BRCA1 and BRCA2 gene mutations. Gynecol Oncol. 2011 May 01; 121(2):358-63. PMID: 21276604; PMCID: PMC3310886.
      Citations: 17     Fields:    Translation:Humans
    211. Westin SN, Sun CC, Lu KH, Schmeler KM, Soliman PT, Lacour RA, Johnson KG, Daniels MS, Arun BK, Peterson SK, Bodurka DC. Satisfaction with ovarian carcinoma risk-reduction strategies among women at high risk for breast and ovarian carcinoma. Cancer. 2011 Jun 15; 117(12):2659-67. PMID: 21656744; PMCID: PMC4254830.
      Citations: 7     Fields:    Translation:HumansPHPublic Health
    212. Cantrell LA, Westin SN, Van Le L. The use of recombinant erythropoietin for the treatment of chemotherapy-induced anemia in patients with ovarian cancer does not affect progression-free or overall survival. Cancer. 2011 Mar 15; 117(6):1220-6. PMID: 21381011.
      Citations: 3     Fields:    Translation:Humans
    213. Tierney B, Westin SN, Schlumbrecht MP, Ramirez PT. Early cervical neoplasia: advances in screening and treatment modalities. Clin Adv Hematol Oncol. 2010 Aug; 8(8):547-55. PMID: 20966891; PMCID: PMC4317338.
      Citations:    Fields:    Translation:HumansPHPublic Health
    214. Westin SN, Broaddus RR, Deng L, McCampbell A, Lu KH, Lacour RA, Milam MR, Urbauer DL, Mueller P, Pickar JH, Loose DS. Molecular clustering of endometrial carcinoma based on estrogen-induced gene expression. Cancer Biol Ther. 2009 Nov; 8(22):2126-35. PMID: 19755863; PMCID: PMC2872176.
      Citations: 18     Fields:    Translation:Humans
    215. Litton JK, Westin SN, Ready K, Sun CC, Peterson SK, Meric-Bernstam F, Gonzalez-Angulo AM, Bodurka DC, Lu KH, Hortobagyi GN, Arun BK. Perception of screening and risk reduction surgeries in patients tested for a BRCA deleterious mutation. Cancer. 2009 Apr 15; 115(8):1598-604. PMID: 19280625; PMCID: PMC2680417.
      Citations: 18     Fields:    Translation:Humans
    216. Zhang Q, Shen Q, Celestino J, Milam MR, Westin SN, Lacour RA, Meyer LA, Shipley GL, Davies PJ, Deng L, McCampbell AS, Broaddus RR, Lu KH. Enhanced estrogen-induced proliferation in obese rat endometrium. Am J Obstet Gynecol. 2009 Feb; 200(2):186.e1-8. PMID: 19185100; PMCID: PMC2880878.
      Citations: 12     Fields:    Translation:Animals
    217. Westin SN, Lacour RA, Urbauer DL, Luthra R, Bodurka DC, Lu KH, Broaddus RR. Carcinoma of the lower uterine segment: a newly described association with Lynch syndrome. J Clin Oncol. 2008 Dec 20; 26(36):5965-71. PMID: 19001318; PMCID: PMC2645115.
      Citations: 56     Fields:    Translation:Humans
    218. Lacour RA, Daniels MS, Westin SN, Meyer LA, Burke CC, Burns KA, Kurian S, Webb NF, Pustilnik TB, Lu KH. What women with ovarian cancer think and know about genetic testing. Gynecol Oncol. 2008 Oct; 111(1):132-6. PMID: 18684498; PMCID: PMC3746752.
      Citations: 28     Fields:    Translation:Humans
    219. Meyer LA, Westin SN, Lu KH, Milam MR. Genetic polymorphisms and endometrial cancer risk. Expert Rev Anticancer Ther. 2008 Jul; 8(7):1159-67. PMID: 18588460; PMCID: PMC5557368.
      Citations: 13     Fields:    Translation:Humans
    220. Westin SN, Bustillos D, Gano JB, Fields MM, Coker AL, Sun CC, Ramondetta LM. Social factors affecting treatment of cervical cancer: ethical issues and policy implications. Obstet Gynecol. 2008 Mar; 111(3):747-51. PMID: 18310380.
      Citations: 7     Fields:    Translation:Humans
    221. Milam MR, Gu J, Yang H, Celestino J, Wu W, Horwitz IB, Lacour RA, Westin SN, Gershenson DM, Wu X, Lu KH. STK15 F31I polymorphism is associated with increased uterine cancer risk: a pilot study. Gynecol Oncol. 2007 Oct; 107(1):71-4. PMID: 17599395.
      Citations: 12     Fields:    Translation:Humans
    222. Westin SN, Skinner EN, Jonsson Funk M, Gehrig PM, Van Le L. Incidence of symptomatic deep venous thrombosis with epoetin alfa or darbepoetin alfa treatment of anemia in patients with ovarian or primary peritoneal cancer. Gynecol Oncol. 2007 May; 105(2):414-7. PMID: 17250880.
      Citations: 2     Fields:    Translation:Humans
    223. Mattsson J, Westin S, Edlund S, Remberger M. Poor oral nutrition after allogeneic stem cell transplantation correlates significantly with severe graft-versus-host disease. Bone Marrow Transplant. 2006 Nov; 38(9):629-33. PMID: 16964269.
      Citations:    
    224. Westin S. The obstetric forceps: shrouded in mystery. Obstet Gynecol Surv. 2006 Jun; 61(6):357-8. PMID: 16719940.
      Citations:    Fields:    Translation:Humans
    225. Llopis J, Westin S, Ricote M, Wang Z, Cho CY, Kurokawa R, Mullen TM, Rose DW, Rosenfeld MG, Tsien RY, Glass CK, Wang J. Ligand-dependent interactions of coactivators steroid receptor coactivator-1 and peroxisome proliferator-activated receptor binding protein with nuclear hormone receptors can be imaged in live cells and are required for transcription. Proc Natl Acad Sci U S A. 2000 Apr 11; 97(8):4363-8. PMID: 10760302; PMCID: PMC18247.
      Citations: 34     Fields:    Translation:HumansCells
    226. Sheppard KA, Rose DW, Haque ZK, Kurokawa R, McInerney E, Westin S, Thanos D, Rosenfeld MG, Glass CK, Collins T. Transcriptional activation by NF-kappaB requires multiple coactivators. Mol Cell Biol. 1999 Sep; 19(9):6367-78. PMID: 10454583; PMCID: PMC84607.
      Citations: 136     Fields:    Translation:AnimalsCells
    227. McInerney EM, Rose DW, Flynn SE, Westin S, Mullen TM, Krones A, Inostroza J, Torchia J, Nolte RT, Assa-Munt N, Milburn MV, Glass CK, Rosenfeld MG. Determinants of coactivator LXXLL motif specificity in nuclear receptor transcriptional activation. Genes Dev. 1998 Nov 01; 12(21):3357-68. PMID: 9808623; PMCID: PMC317227.
      Citations: 181     Fields:    Translation:AnimalsCells
    228. Nolte RT, Wisely GB, Westin S, Cobb JE, Lambert MH, Kurokawa R, Rosenfeld MG, Willson TM, Glass CK, Milburn MV. Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-gamma. Nature. 1998 Sep 10; 395(6698):137-43. PMID: 9744270.
      Citations: 515     Fields:    Translation:HumansCells
    229. Westin S, Kurokawa R, Nolte RT, Wisely GB, McInerney EM, Rose DW, Milburn MV, Rosenfeld MG, Glass CK. Interactions controlling the assembly of nuclear-receptor heterodimers and co-activators. Nature. 1998 Sep 10; 395(6698):199-202. PMID: 9744281.
      Citations: 94     Fields:    Translation:Cells
    230. Torchia J, Rose DW, Inostroza J, Kamei Y, Westin S, Glass CK, Rosenfeld MG. The transcriptional co-activator p/CIP binds CBP and mediates nuclear-receptor function. Nature. 1997 Jun 12; 387(6634):677-84. PMID: 9192892.
      Citations: 363     Fields:    Translation:HumansAnimalsCells
    231. Andersen E, Grimsmo A, Haugen L, Relling SA, Westin S. [What is the situation for rehabilitation money recipients after the support ceases?]. Tidsskr Nor Laegeforen. 1996 Sep 20; 116(22):2690-4. PMID: 8928150.
      Citations:    Fields:    Translation:Humans
    232. Getz L, Westin S. [Assessment by consulting physicians and general practitioners about complex disability pension matters]. Tidsskr Nor Laegeforen. 1995 May 30; 115(14):1748-53. PMID: 7785037.
      Citations: 1     Fields:    Translation:Humans
    233. Getz L, Larssen KE, Dahl B, Westin S. Health problems in Norwegians travelling to distant countries. Scand J Prim Health Care. 1990 Jul; 8(2):95-100. PMID: 2218161.
      Citations: 1     Fields:    Translation:HumansPHPublic Health
    234. Westin S. The structure of a factory closure: individual responses to job-loss and unemployment in a 10-year controlled follow-up study. Soc Sci Med. 1990; 31(12):1301-11. PMID: 2287959.
      Citations: 3     Fields:    Translation:Humans
    235. Westin S, Schlesselman JJ, Korper M. Long-term effects of a factory closure: unemployment and disability during ten years' follow-up. J Clin Epidemiol. 1989; 42(5):435-41. PMID: 2732771.
      Citations: 10     Fields:    Translation:Humans
    236. Westin S. [Treatment of young drug addicts in a psychiatric hospital. Experience and conclusions from the first year with a treatment program for young drug addicts at the Neeveng?rden hospital, 1971]. Tidsskr Nor Laegeforen. 1973 Aug 30; 93(24):1662-8. PMID: 4769492.
      Citations:    Fields:    Translation:HumansAnimals
    237. MET nucleotide variations and amplification in advanced ovarian cancer. Oncoscience. 1:5-13.
    238. Molecular targeted therapies in endometrial cancer. 187-213.
    239. Application of Immunohistochemistry and Molecular Diagnostics to Clinically Relevant Problems in Endometrial Cancer. Surgical Pathology Clinics. 5:859-878.
    240. Status epilepticus associated with platinum chemotherapy in a patient with cervical cancer. BMC Cancer. 15.
    241. Quality of life after radical trachelectomy for early-stage cervical cancer. Gynecologic Oncology. 143:596-603.
    242. Survivors of gynecologic malignancies. Journal of Cancer Survivorship.
    243. The rise of genomic profiling in ovarian cancer. Expert Review of Molecular Diagnostics. 16:1337-1351.
    244. PTEN loss is a context-dependent outcome determinant in obese and non-obese endometrioid endometrial cancer patients. Molecular Oncology. 9:1694-1703.
    245. Targets by organ site.
    246. Lymphovascular space invasion portends poor prognosis in low-risk endometrial cancer. International Journal of Gynecological Cancer. 25:1292-1299.
    247. Continuous anti-angiogenic therapy after tumor progression in patients with recurrent high-grade epithelial ovarian cancer. Oncotarget. 7:35132-35143.
    248. Rational selection of biomarker driven therapies for gynecologic cancers. Gynecologic Oncology. 141:65-71.
    249. Targeted Therapy and Molecular Genetics. 539-560.
    250. Impact of lymph node ratio and adjuvant therapy in node-positive endometrioid endometrial cancer. International Journal of Gynecological Cancer. 25:1437-1444.
    251. A non-pregnant woman with elevated beta-HCG. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring. 17:49-52.
    252. Targets by organ site.
    253. In reply. Obstetrics and Gynecology. 118:710-711.
    254. Individualized Medicine in Ovarian Cancer. Gynecologic Oncology. 144:229-231.
    255. Prospective evaluation of the molecular effects of metformin on the endometrium in women with newly diagnosed endometrial cancer. Gynecologic Oncology. 143:466-471.
    256. Personalized comprehensive molecular profiling of high risk osteosarcoma. Oncotarget. 6:40642-40654.
    257. Gynecologic cancer survivorship management. 125-143.
    258. Targets by organ site.
    259. Integrative protein-based prognostic model for early-stage endometrioid endometrial cancer. Clinical Cancer Research. 22:513-523.
    WESTIN's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (694)
    Explore
    _
    Co-Authors (161)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _